<SEC-DOCUMENT>0001213900-25-115921.txt : 20251128
<SEC-HEADER>0001213900-25-115921.hdr.sgml : 20251128
<ACCEPTANCE-DATETIME>20251128130050
ACCESSION NUMBER:		0001213900-25-115921
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20251126
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20251128
DATE AS OF CHANGE:		20251128

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Inmune Bio, Inc.
		CENTRAL INDEX KEY:			0001711754
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				475205835
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38793
		FILM NUMBER:		251534326

	BUSINESS ADDRESS:	
		STREET 1:		225 NE MIZNER BLVD, SUITE 640
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33432
		BUSINESS PHONE:		8589643720

	MAIL ADDRESS:	
		STREET 1:		225 NE MIZNER BLVD, SUITE 640
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33432
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ea0267546-8k_inmune.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-roles="http://fasb.org/us-roles/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:INMB="http://inmunebio.com/20251126">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02E_US%2DGAAP%2D2025 -->
<!-- Field: Set; Name: xdx; ID: xdx_03F_INMB_inmunebio.com_20251126 -->
<!-- Field: Set; Name: xdx; ID: xdx_048_20251126_20251126 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_053_edei%2D%2DEntityCentralIndexKey_0001711754 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2025-11-26" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2025-11-26" id="Fact000004" name="dei:EntityCentralIndexKey">0001711754</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="inmb-20251126.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2025-11-26">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001711754</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-11-26</xbrli:startDate>
        <xbrli:endDate>2025-11-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FORM
<span id="xdx_902_edei--DocumentType_c20251126__20251126_zwJ2uMRMHbo8"><ix:nonNumeric contextRef="AsOf2025-11-26" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CURRENT
REPORT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date
of Report (Date of earliest event reported): <span id="xdx_90E_edei--DocumentPeriodEndDate_c20251126__20251126_z0wHAdBcKgi7"><ix:nonNumeric contextRef="AsOf2025-11-26" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">November 26, 2025</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 100%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_903_edei--EntityRegistrantName_c20251126__20251126_zyMgOKngSlMk"><ix:nonNumeric contextRef="AsOf2025-11-26" id="Fact000011" name="dei:EntityRegistrantName">INMUNE
    BIO INC.</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
    name of registrant as specified in charter)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90E_edei--EntityIncorporationStateCountryCode_c20251126__20251126_zzRwduKJJ2V4"><ix:nonNumeric contextRef="AsOf2025-11-26" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_905_edei--EntityFileNumber_c20251126__20251126_z1FPqUQ1lPg2"><ix:nonNumeric contextRef="AsOf2025-11-26" id="Fact000013" name="dei:EntityFileNumber">001-38793</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_907_edei--EntityTaxIdentificationNumber_c20251126__20251126_zpJn9xUifH52"><ix:nonNumeric contextRef="AsOf2025-11-26" id="Fact000014" name="dei:EntityTaxIdentificationNumber">47-5205835</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
    or other jurisdiction</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission
    File Number)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS
    Employer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of
    incorporation)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
    No.)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_90B_edei--EntityAddressAddressLine1_c20251126__20251126_z6IamsSSnEhg"><ix:nonNumeric contextRef="AsOf2025-11-26" id="Fact000015" name="dei:EntityAddressAddressLine1">225
NE Mizner Blvd.</ix:nonNumeric></span>, <span id="xdx_903_edei--EntityAddressAddressLine2_c20251126__20251126_zktgkafUiBvh"><ix:nonNumeric contextRef="AsOf2025-11-26" id="Fact000016" name="dei:EntityAddressAddressLine2">Suite 640</ix:nonNumeric></span>, <span id="xdx_905_edei--EntityAddressCityOrTown_c20251126__20251126_zSXXNZnMG9z9"><ix:nonNumeric contextRef="AsOf2025-11-26" id="Fact000017" name="dei:EntityAddressCityOrTown">Boca Raton</ix:nonNumeric></span>, <span id="xdx_90C_edei--EntityAddressStateOrProvince_c20251126__20251126_zkxLMskUppS2"><ix:nonNumeric contextRef="AsOf2025-11-26" format="ixt-sec:stateprovnameen" id="Fact000018" name="dei:EntityAddressStateOrProvince">Florida</ix:nonNumeric></span> <span id="xdx_900_edei--EntityAddressPostalZipCode_c20251126__20251126_z3RiDpjQHejb"><ix:nonNumeric contextRef="AsOf2025-11-26" id="Fact000019" name="dei:EntityAddressPostalZipCode">33432</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
of Principal Executive Offices) (Zip Code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">(<span id="xdx_90F_edei--CityAreaCode_c20251126__20251126_zwmh9wmoXMw2"><ix:nonNumeric contextRef="AsOf2025-11-26" id="Fact000020" name="dei:CityAreaCode">561</ix:nonNumeric></span>)
<span id="xdx_905_edei--LocalPhoneNumber_c20251126__20251126_zJRL4LgXrK0h"><ix:nonNumeric contextRef="AsOf2025-11-26" id="Fact000021" name="dei:LocalPhoneNumber">710-0512</ix:nonNumeric></span> </span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant&#8217;s
Telephone Number, Including Area Code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Not
Applicable</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Former
Name or Former Address, If Changed Since Last Report)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (<span style="text-decoration: underline">see</span> General Instruction A.2. below):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_edei--WrittenCommunications_c20251126__20251126_zCxPuwOosv8d"><ix:nonNumeric contextRef="AsOf2025-11-26" format="ixt:booleanfalse" id="Fact000022" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written
    communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_edei--SolicitingMaterial_c20251126__20251126_zkNE7oImNGy7"><ix:nonNumeric contextRef="AsOf2025-11-26" format="ixt:booleanfalse" id="Fact000023" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting
    material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_edei--PreCommencementTenderOffer_c20251126__20251126_zpp85Za4fzcg"><ix:nonNumeric contextRef="AsOf2025-11-26" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_edei--PreCommencementIssuerTenderOffer_c20251126__20251126_z7GQgCzc6Sq5"><ix:nonNumeric contextRef="AsOf2025-11-26" format="ixt:booleanfalse" id="Fact000025" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 35%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title
    of each class</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 26%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading
    Symbol(s)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; width: 35%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
    of each exchange on which registered</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_edei--Security12bTitle_c20251126__20251126_zIkFDOSsC4p5"><ix:nonNumeric contextRef="AsOf2025-11-26" id="Fact000026" name="dei:Security12bTitle">Common
    Stock, par value $0.001 per shares</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_edei--TradingSymbol_c20251126__20251126_z2PUGhEy23Ha"><ix:nonNumeric contextRef="AsOf2025-11-26" id="Fact000027" name="dei:TradingSymbol">INMB</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    <span id="xdx_908_edei--SecurityExchangeName_c20251126__20251126_zf4VInjpTy4d"><ix:nonNumeric contextRef="AsOf2025-11-26" format="ixt-sec:exchnameen" id="Fact000028" name="dei:SecurityExchangeName">NASDAQ</ix:nonNumeric></span> Stock Market LLC</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167; 240.12b-2 of this chapter).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
growth company <span id="xdx_908_edei--EntityEmergingGrowthCompany_c20251126__20251126_zqklQl3cFWOh"><ix:nonNumeric contextRef="AsOf2025-11-26" format="ixt:booleanfalse" id="Fact000029" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mart if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Moss
Employment Agreement </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 26, 2025, INmune Bio Inc. (the &#8220;Company&#8221;) and David J. Moss, the Company&#8217;s President and Chief Executive entered
into an employment agreement. Pursuant to the employment agreement, beginning on November 1, 2025, Mr. Moss will be paid a base salary
of $500,000 per annum and is eligible to receive an annual discretionary bonus with a target amount of 50% of his annual base salary,
prorated for the number of days employed during the applicable calendar year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Moss was also granted an option to purchase 800,000 shares of the Company&#8217;s common stock under the Second Amended and Restated
INmune Bio Inc. 2021 Stock Incentive Plan (as amended from time to time, the &#8220;Plan&#8221;). Upon a Change of Control (as defined
in the Plan), any unvested portion of the option will become immediately vested and exercisable, subject to Mr. Moss&#8217;s continued
service up to the closing date of the Change of Control.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event of an Involuntary Termination (as defined in the employment agreement), Mr. Moss will be entitled to receive (i) 18 months
of his base salary, paid in accordance with the Company&#8217;s regular payroll, (ii) a prorated annual bonus, and (iii) payment of COBRA
premiums (or a taxable equivalent payment) for up to 18 months, in each case subject to his execution and non-revocation of a separation
agreement and release of claims.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Ellspermann
Employment Agreement </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 26, 2025, the Company and Cory Ellspermann, the Company&#8217;s Chief Financial Officer entered into an employment agreement.
Pursuant to the employment agreement, beginning on November 1, 2025, Mr. Ellspermann will be paid a base salary of $275,000 per annum
and is eligible to receive an annual discretionary bonus with a target amount of 40% of his annual base salary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Ellspermann was also granted an option to purchase 300,000 shares of the Company&#8217;s common stock under the Plan. Upon a Change of
Control (as defined in the Plan), any unvested portion of the option will become immediately vested and exercisable, subject to Mr. Ellspermann&#8217;s
continued service up to the closing date of the Change of Control.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event of an Involuntary Termination (as defined in the employment agreement) Mr. Ellspermann will be entitled to receive (i) 18 months
of his base salary, paid in accordance with the Company&#8217;s regular payroll, (ii) a prorated annual bonus, and (iii) payment of COBRA
premiums (or a taxable equivalent payment) for up to 18 months, in each case subject to his execution and non-revocation of a separation
agreement and release of claims.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Lowdell
Employment Agreement </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 26, 2025, INmune Bio International Limited, a wholly owned subsidiary of the Company (the &#8220;Subsidiary&#8221;), entered
into an employment agreement with Mark Lowdell, who currently serves as the Chief Scientific Officer of the Company, effective November
1, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the employment agreement, Mr. Lowdell continues to serve as Chief Scientific Officer of both the Subsidiary and the Company. Mr. Lowdell
remains an employee of the Subsidiary and may perform services for the Company under a secondment arrangement if such services exceed
reasonable time commitments. All compensation and benefits will be paid by the Subsidiary, which may recharge costs to the Company as
appropriate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the employment agreement, Mr. Lowdell will receive a base salary of &#163;300,000 per annum, payable monthly in arrears, and will be
eligible to be considered for an annual discretionary bonus of up to 20% of base salary, subject to performance criteria established
by the Board. Mr. Lowdell is eligible to participate in the Subsidiary&#8217;s pension scheme and other employee benefit programs available
to senior personnel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Either
party may terminate employment upon three (3) months&#8217; written notice, or payment in lieu of notice by the Subsidiary. The Subsidiary
may terminate employment without notice for gross misconduct or other grounds under English law. If the Subsidiary terminates Mr. Lowdell&#8217;s
employment other than for cause, death, or permanent disability, Mr. Lowdell is entitled to severance equal to 18 months of base salary,
subject to statutory deductions and conditioned on Mr. Lowdell&#8217;s timely execution of a release of claims. The severance is inclusive
of statutory or contractual notice pay or other termination entitlements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
employment agreement includes customary confidentiality, inventions, and intellectual property assignment obligations, as well as provisions
requiring the return of Company property and compliance with Company policies. Mr. Lowdell is entitled to indemnification to the fullest
extent permitted by law and under the organizational documents of the Subsidiary and the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing summaries of the employment agreements of Messrs. Moss, Ellspermann and Lowdell are qualified in their entirety by
reference to the full text of such agreements, which are filed as Exhibits 10.1, 10.2 and 10.3, respectively, to this Current Report
on Form 8-K and incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
9.01 Financial Statements and Exhibits.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Exhibits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
    No.</b></span></td>
    <td style="padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 90%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="ea026754601ex10-1_inmune.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Agreement, dated November 26, 2025, between INmune Bio Inc. and David Moss</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="ea026754601ex10-2_inmune.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Agreement, dated November 26, 2025, between INmune Bio Inc. and Cory Ellspermann</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea026754601ex10-3_inmune.htm">Employment Agreement, dated November 26, 2025, between INmune Bio International Limited and Mark Lowdell</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
    Page Interactive Data File (embedded within the Inline XBRL document).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INMUNE
    BIO INC.</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    November 28, 2025</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 35%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    David Moss</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
    Moss</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">3</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjdEKgkAQRb/Afxj2WUoNffAxKYksRCR6XXKKJd2R2c3qk/rLViUaBoaZe88dIXyR01a1yHBeVwXU2PWttAgVXpFRX9A5st0+BTcrvCljWWo7rT8wI8egY5LFSrr75ByUwSaFMFxGyTKKIYjTMIDyILxRz0hfVYPaKtmC1A2UTD0rtJLfc0ItX6Spe0+fTshGkXZxi2CWPxAFYQRHGuST+G6gKDLh+VN5Imd69M61eVnUIwmbFjv3zsz0v70vycBKWQ== -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ea026754601ex10-1_inmune.htm
<DESCRIPTION>EMPLOYMENT AGREEMENT, DATED NOVEMBER 26, 2025, BETWEEN INMUNE BIO INC. AND DAVID MOSS
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>INmune Bio Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>225 NE Mizner Blvd., Suite 640</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Boca Raton, Florida 33432</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">November 26, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">David J. Moss</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">225 NE Mizner Blvd., Suite 640</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Boca Raton FL 33432</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Re:</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Offer of Employment</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Dear Mr. Moss:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: left">INmune Bio Inc. (the
&ldquo;<B>Company</B>&rdquo;) is pleased to offer you continued at-will employment in the position of President and Chief Executive Officer
on the terms and conditions set forth in this letter agreement (the &ldquo;<B>Agreement</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>1. Employment
by the Company.</B> Your employment with the Company shall continue on these terms effective as of November 1, 2025, or such date as otherwise
agreed to by you and the Company (such actual date your employment begins on these terms, the (&ldquo;<B>Effective Date</B>&rdquo;)).
This is an exempt position, and during your employment with the Company, you will devote your best efforts and substantially all of your
business time and attention to the business of the Company, except for approved vacation periods and reasonable periods of illness or
other incapacities permitted by the Company&rsquo;s general employment policies. You shall perform such duties as are required by the
Company&rsquo;s Board of Directors (&ldquo;<B>Board</B>&rdquo;), to whom you will report. Your primary work location shall be at 225 NE
Mizner Blvd, Suite 640, Boca Raton FL 33432. The Company reserves the right to reasonably require you to perform your duties at places
other than your primary office location from time to time, and to require reasonable business travel. The Company may modify your job
title and duties as it deems necessary and appropriate in light of the</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Company&rsquo;s needs and interests from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <B>2.</B> <B>Compensation.</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>2.1 Base Salary.</B>
For services to be rendered hereunder, you shall receive a base salary at the rate of $500,000 per year (the &ldquo;<B>Base Salary</B>&rdquo;),
subject to standard payroll deductions and withholdings and payable in accordance with the Company&rsquo;s regular payroll schedule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>2.2
Annual Bonus.</B> You will be eligible for an annual discretionary bonus with a target amount of 50% of your then current annual
Base Salary, prorated for the number of days employed in a calendar year (the &ldquo;<B>Annual Bonus</B>&rdquo;). Whether you
receive an Annual Bonus for any given year, and the amount of any such Annual Bonus, will be determined by the Board and/or its
Compensation Committee in its discretion based upon the achievement of corporate and/or individual objectives and milestones that
are determined in the sole discretion of the Board. If your employment terminates for any reason prior to the date such Annual
Bonus, if any, is paid, then you will not have earned an Annual Bonus for that year and will not receive any portion of it, except
as provided in Section 8. The Annual Bonus, if earned, shall be paid to you in a lump sum
no later than March 15<FONT STYLE="font-size: 10pt"><SUP>th</SUP></FONT> of the calendar year that follows the performance year,
subject to applicable payroll deductions and withholdings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>2.3 Equity</B>.
Subject to approval by the Board, you shall be granted an option to purchase 800,000 shares of common stock of the Company (the &ldquo;<B>Option</B>&rdquo;)
pursuant to the Second Amended and Restated INmune Bio Inc. 2021 Stock Incentive Plan. (as amended from time to time, the &ldquo;<B>Plan</B>&rdquo;).
The exercise price of the Option shall be the minimum permissible amount, and such exercise price as well as all other matters related
to the Option, will be governed by and subject to the terms and conditions set forth in the Plan, and the stock option agreement you will
be required to execute. Upon a Change of Control (as defined in the Plan), the vesting and exercisability of all unvested shares subject
to the Option shall accelerate and become immediately vested and exercisable as of the date of the closing of the Change of Control (the
&ldquo;<B>CIC Equity Acceleration</B>&rdquo;). The CIC Equity Acceleration shall be subject to your Continuous Service (as defined in
the Plan) up to and including the closing date of such Change of Control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>3. Reasonable
Business Expenses.</B> You will be eligible for reimbursement of all reasonable, necessary and documented out-of-pocket business, entertainment,
and travel expenses incurred by you in connection with the performance of your duties hereunder in accordance with the Company&rsquo;s
expense reimbursement policies and procedures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>4. Paid
Time Off; Holidays.</B> You will initially be eligible to accrue up to [three weeks] of paid time off during each calendar year, subject
to applicable maximum accrual caps, in accordance with the Company&rsquo;s paid time off policies as in effect from time to time. You
will also be eligible for certain paid holidays pursuant to Company policy. The Company reserves the right to cancel or change its policies
regarding paid time off, paid sick leave and/or holidays from time to time without amendment of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>5.
Company Policies; Standard Company Benefits</B>. The employment relationship between the parties shall be governed by the general
employment policies and practices of the Company, except that when the terms of this Agreement differ from or are in conflict with
the Company&rsquo;s general employment policies or practices, this Agreement shall control. You shall be entitled to participate in
all employee benefit programs for which you are eligible under the terms and conditions of the benefit plans that may be in effect
from time to time and provided by the Company to its employees. The Company reserves the right to cancel or change the benefit plans
or programs it offers to its employees at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>6. At-Will
Employment.</B> Your employment relationship is at-will. Either you or the Company may terminate the employment relationship at any time,
with or without cause or advance notice. Upon termination of your employment for any reason, you shall resign from all positions and terminate
any relationships as an employee, advisor, officer or director with the Company and any of its affiliates, each effective on the date
of termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>7.
Outside Activities During Employment.</B> Except with the prior written consent of the Board, you will not during the term of your
employment with the Company undertake or engage in any other employment, occupation or business enterprise, other than ones in which
you are a passive investor. You may engage in civic and not-for-profit activities and be a member of the board of directors of other
companies so long as such activities do not materially interfere with the performance of your duties hereunder and such other
companies are not competitive with the Company&rsquo;s business. You agree not to acquire, assume or participate in, directly or
indirectly, any position, material investment or interest known to be adverse or antagonistic to the Company, its business or
prospects, financial or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B></B></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <B>8.</B> <B>Termination; Severance.</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>8.1 Compensation
upon Termination.</B> Upon the termination of your employment for any reason, the Company shall pay you all of your accrued and unpaid
wages earned through your last day of employment (the &ldquo;<B>Separation Date</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>8.2 Involuntary
Termination.</B> If you are subject to an Involuntary Termination (as defined below), and provided that you remain in compliance with
the terms of this Agreement (including the conditions described in <U>Section 8.4</U> below), the Company shall provide you with the following
benefits (the &ldquo;<B>Severance Benefits</B>&rdquo;):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>(a) Cash Severance.</B> The Company
shall pay you, as severance, the equivalent of 18 months (the &ldquo;<B>Severance Period</B>&rdquo;) of your Base Salary in effect
as of the Separation Date, subject to standard payroll deductions and withholdings. The Severance will be paid as a continuation on
the Company&rsquo;s regular payroll, beginning no later than the first regularly-scheduled payroll date following the sixtieth
(60<FONT STYLE="font-size: 10pt"><SUP>th</SUP></FONT>) day after your Separation from Service, provided the Separation Agreement (as
discussed in <U>Section 8.4</U>) has become effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>(b) Prorated
Annual Bonus.</B> You will be eligible to receive a prorated Annual Bonus (calculated as the Annual Bonus that would have been paid for
the entire calendar year multiplied by a fraction, the numerator of which is equal to the number of days you worked in the applicable
calendar year, and the denominator of which is equal to the total number of days in such year). The prorated Annual Bonus, if any, will
be paid to you, subject to standard payroll deductions and withholdings, at the time such bonus is paid to similarly situated employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>(c) Payment
of Continued Group Health Plan Benefits.</B> If you are eligible for and timely elect continued group health plan coverage under the Consolidated
Omnibus Budget Reconciliation Act of 1985 or any state law of similar effect (&ldquo;<B>COBRA</B>&rdquo;) following your Involuntary Termination,
the Company will pay your COBRA group health insurance premiums or equivalent of COBRA if the company is not eligible for COBRA for you
and your eligible dependents directly to the insurer until the earliest of (A) the end of the period immediately following your Involuntary
Termination that is equal to the Severance Period (the &ldquo;<B>COBRA Payment Period</B>&rdquo;), (B) the expiration of your eligibility
for continuation coverage under COBRA, or (C) the date when you become eligible for substantially equivalent health insurance coverage
in connection with new employment or self-employment. For purposes of this Section, references to COBRA premiums shall not include any
amounts payable by you under a Section 125 health care reimbursement plan under the Code. Notwithstanding the foregoing, if at any time
the Company determines, in its sole discretion, that it cannot pay the COBRA premiums without potentially incurring financial costs or
penalties under applicable law (including, without limitation, Section 2716 of the Public Health Service Act), then regardless of whether
you elect continued health coverage under COBRA, and in lieu of providing the COBRA premiums, the Company will instead pay you on the
last day of each remaining month of the COBRA Payment Period, a fully taxable cash payment equal to the COBRA premiums for that month,
subject to applicable tax withholdings (such amount, the &ldquo;<B>Special Severance Payment</B>&rdquo;), which payments shall continue
until the earlier of expiration of the COBRA Payment Period or the date when you become eligible for substantially equivalent health insurance
coverage in connection with new employment or self-employment. On the first payroll date following the effectiveness of the Separation
Agreement, the Company will make the first payment to the insurer under this clause (and, in the case of the Special Severance Payment,
such payment will be to you, in a lump sum) equal to the aggregate amount of payments that the Company would have paid through such date
had such payments instead commenced on the Separation Date, with the balance of the payments paid thereafter on the schedule described
above. If you become eligible for coverage under another employer&rsquo;s group health plan, you must immediately notify the Company of
such event, and all payments and obligations under this subsection shall cease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>8.3 Termination
for Cause; Resignation Without Good Reason; Death or Disability.</B> If you resign without Good Reason, or the Company terminates your
employment for Cause, upon dissolution or cessation of the Company, or upon your death or disability, then (a) you will no longer vest
in the Option, (b) all payments of compensation by the Company to you hereunder will terminate immediately (except as to amounts already
earned), and (c) you will not be entitled to any Severance Benefits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>8.4 Conditions to
Receipt of Severance Benefits.</B> The receipt of the Severance Benefits will be subject to you signing and not revoking a separation
agreement and general release of claims in a form reasonably satisfactory to the Company (the &ldquo;<B>Separation Agreement</B>&rdquo;)
by no later than the sixtieth (60th) day after the Separation Date (&ldquo;<B>Release Deadline</B>&rdquo;). No Severance Benefits will
be paid or provided until the Separation Agreement becomes effective. You shall also resign from all positions and terminate any relationships
as an employee, advisor, officer or director with the Company and any of its affiliates, each effective on the Separation Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"><B>9. Definitions.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>9.1 Cause.</B> For
purposes of this Agreement, <B>&ldquo;Cause&rdquo;</B> for termination means: (a) commission of any felony or crime involving dishonesty;
(b) participation in any fraud against the Company; (c) material breach of your duties to the Company; (d) persistent unsatisfactory performance
of job duties after written notice from the Board and an opportunity to cure (if deemed curable by the Company in its sole discretion);
(e) intentional damage to any material property of the Company; (f) misconduct, or other violation of Company policy that causes material
harm; (g) breach of this Agreement, the Confidentiality Agreement (as defined below), or any other written agreement with the Company;
or (h) conduct by you which in the good faith and reasonable determination of the Board demonstrates gross unfitness to serve.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>9.2 Code.</B> For
purposes of this Agreement, <B>&ldquo;Code&rdquo;</B> means the U.S. Internal Revenue Code of 1986 (as it has been and may be amended
from time to time) and any regulations and guidance that has been promulgated or may be promulgated from time to time thereunder and any
state law of similar effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>9.3
Good Reason.</B> For purposes of this Agreement, you shall have &ldquo;<B>Good Reason</B>&rdquo; for resignation from employment
with the Company if any of the following actions are taken by the Company without your prior written consent: (a) a material
reduction in your Base Salary, which the parties agree is a reduction of at least 10% of your Base Salary (unless pursuant to a
salary reduction program applicable generally to the Company&rsquo;s similarly situated employees); (b) a material reduction in your
duties (including responsibilities and/or authorities), <I>provided, however,</I> that a change in job position (including a change
in title) shall not be deemed a &ldquo;material reduction&rdquo; in and of itself unless your new duties are materially reduced from
the prior duties; or (c) relocation of your principal place of employment to a place that increases your one-way commute by more
than fifty (50) miles as compared to your then-current principal place of employment immediately prior to such relocation. In order
to resign for Good Reason, you must provide written notice to the Company&rsquo;s Board within 30 days after the first occurrence of
the event giving rise to Good Reason setting forth the basis for your resignation, allow the Company at least 30 days from receipt
of such written notice to cure such event, and if such event is not reasonably cured within such period, you must resign from all
positions you then hold with the Company not later than 90 days after the expiration of the cure period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>9.4 Involuntary
Termination.</B> For purposes of this Agreement, &ldquo;<B>Involuntary Termination</B>&rdquo; means a termination of your employment with
the Company pursuant to either (i) a termination initiated by the Company without Cause, or (ii) your resignation for Good Reason, and
provided in either case such termination constitutes a Separation from Service. An Involuntary Termination does not include any other
termination of your employment, including a termination due to your death or disability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>9.5 Separation from
Service.</B> For purposes of this Agreement, &ldquo;Separation from Service&rdquo; means a &ldquo;separation from service&rdquo;, as defined
under Treasury Regulation Section 1.409A-1(h).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>10. Proprietary
Information Obligations.</B> As a condition of your continued employment, you shall continue to abide by the Company&rsquo;s standard
form of Confidential Information and Invention Assignment Agreement (the &ldquo;<B>Confidentiality Agreement</B>&rdquo;), attached as
<B><U>Exhibit A</U></B>. In your work for the Company, you will be expected not to use or disclose any confidential information, including
trade secrets, of any former employer or other person to whom you have an obligation of confidentiality. Rather, you will be expected
to use only that information which is generally known and used by persons with training and experience comparable to your own, which is
common knowledge in the industry or otherwise legally in the public domain, or which is otherwise provided or developed by the Company.
You agree that you will not bring onto Company premises any unpublished documents or property belonging to any former employer or other
person to whom you have an obligation of confidentiality. You hereby represent that you have disclosed to the Company any contract you
have signed that may restrict your activities on behalf of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>11.
Section 409A.</B> It is intended that all of the severance benefits and other payments payable under this Agreement satisfy, to the
greatest extent possible, the exemptions from the application of Code Section 409A provided under Treasury Regulations Sections
1.409A 1(b)(4), 1.409A 1(b)(5) and 1.409A 1(b)(9), and this Agreement will be construed to the greatest extent possible as
consistent with those provisions, and to the extent not so exempt, this Agreement (and any definitions hereunder) will be construed
in a manner that complies with Section 409A. For all purposes of Code Section 409A (including, without limitation, for purposes of
Treasury Regulations Sections 1.409A 2(b)(2)(i) and (iii)), your right to receive any installment payments under this Agreement
(whether severance payments, reimbursements or otherwise) shall be treated as a right to receive a series of separate payments and,
accordingly, each installment payment hereunder shall at all times be considered a separate and distinct payment. Notwithstanding
any provision to the contrary in this Agreement, if you are deemed by the Company at the time of your Separation from Service to be
a &ldquo;specified employee&rdquo; for purposes of Code Section 409A(a)(2)(B)(i), and if any of the payments upon Separation from
Service set forth herein and/or under any other agreement with the Company are deemed to be &ldquo;deferred compensation,&rdquo;
then to the extent delayed commencement of any portion of such payments is required in order to avoid a prohibited distribution
under Code Section 409A(a)(2)(B)(i) and the related adverse taxation under Section 409A, such payments shall not be provided to you
prior to the earliest of (i) the first date following expiration of the six-month period following the date of your Separation from
Service with the Company, (ii) the date of your death or (iii) such earlier date as permitted under Section 409A without the
imposition of adverse taxation. Upon the first business day following the expiration of such applicable Code Section
409A(a)(2)(B)(i) period, all payments deferred pursuant to this Paragraph shall be paid in a lump sum to you, and any remaining
payments due shall be paid as otherwise provided herein or in the applicable agreement. No interest shall be due on any amounts so
deferred. If the severance benefits are not covered by one or more exemptions from the application of Section 409A and the Release
Deadline occurs in the calendar year following the calendar year of your Separation from Service, the Separation Agreement will not
be deemed effective any earlier than the Release Deadline for purposes of determining the timing of provision of any severance
benefits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>12. Section 280G.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: left">If any payment or
benefit you will or may receive from the Company or otherwise (a &ldquo;<B>280G Payment</B>&rdquo;) would (i) constitute a &ldquo;parachute
payment&rdquo; within the meaning of Section 280G of the Code, and (ii) but for this sentence, be subject to the excise tax imposed by
Section 4999 of the Code (the &ldquo;<B>Excise Tax</B>&rdquo;), then any such 280G Payment pursuant to this Agreement or otherwise (a
&ldquo;<B>Payment</B>&rdquo;) shall be equal to the Reduced Amount. The &ldquo;<B>Reduced Amount</B>&rdquo; shall be either (x) the largest
portion of the Payment that would result in no portion of the Payment (after reduction) being subject to the Excise Tax or (y) the largest
portion, up to and including the total, of the Payment, whichever amount (i.e., the amount determined by clause (x) or by clause (y)),
after taking into account all applicable federal, state and local employment taxes, income taxes, and the Excise Tax (all computed at
the highest applicable marginal rate), results in your receipt, on an after-tax basis, of the greater economic benefit notwithstanding
that all or some portion of the Payment may be subject to the Excise Tax. If a reduction in a Payment is required pursuant to the preceding
sentence and the Reduced Amount is determined pursuant to clause (x) of the preceding sentence, the reduction shall occur in the manner
(the &ldquo;<B>Reduction Method</B>&rdquo;) that results in the greatest economic benefit for you. If more than one method of reduction
will result in the same economic benefit, the items so reduced will be reduced pro rata (the &ldquo;<B>Pro Rata Reduction Method</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Notwithstanding the
foregoing, if the Reduction Method or the Pro Rata Reduction Method would result in any portion of the Payment being subject to taxes
pursuant to Section 409A that would not otherwise be subject to taxes pursuant to Section 409A, then the Reduction Method and/or the Pro
Rata Reduction Method, as the case may be, shall be modified so as to avoid the imposition of taxes pursuant to Section 409A as follows:
(A) as a first priority, the modification shall preserve to the greatest extent possible, the greatest economic benefit for you as determined
on an after-tax basis; (B) as a second priority, Payments that are contingent on future events (e.g., being terminated without Cause),
shall be reduced (or eliminated) before Payments that are not contingent on future events; and (C) as a third priority, Payments that
are &ldquo;deferred compensation&rdquo; within the meaning of Section 409A shall be reduced (or eliminated) before Payments that are not
deferred compensation within the meaning of Section 409A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Unless you and the
Company agree on an alternative accounting firm, the accounting firm engaged by the Company for general tax compliance purposes as of
the day prior to the effective date of the change in control transaction triggering the Payment shall perform the foregoing calculations.
If the accounting firm so engaged by the Company is serving as accountant or auditor for the individual, entity or group effecting the
change in control transaction, the Company shall appoint a nationally recognized accounting firm to make the determinations required hereunder.
The Company shall bear all expenses with respect to the determinations by such accounting firm required to be made hereunder. The Company
shall use commercially reasonable efforts to cause the accounting firm engaged to make the determinations hereunder to provide its calculations,
together with detailed supporting documentation, to you and the Company within fifteen (15) calendar days after the date on which your
right to a 280G Payment becomes reasonably likely to occur (if requested at that time by you or the Company) or such other reasonable
time as requested by you or the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: left">If you receive a
Payment for which the Reduced Amount was determined pursuant to clause (x) of the first paragraph of this Section and the Internal Revenue
Service determines thereafter that some portion of the Payment is subject to the Excise Tax, you shall promptly return to the Company
a sufficient amount of the Payment (after reduction pursuant to clause (x) of the first paragraph of this Section so that no portion of
the remaining Payment is subject to the Excise Tax). For the avoidance of doubt, if the Reduced Amount was determined pursuant to clause
(y) in the first paragraph of this Section, you shall have no obligation to return any portion of the Payment pursuant to the preceding
sentence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>13. Arbitration of All Disputes.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>13.1
Agreement to Arbitrate</B>. To ensure the timely and economical resolution of disputes that may arise between you and the Company,
both you and the Company mutually agree that pursuant to the Federal Arbitration Act, 9 U.S.C. &sect;1-16, and to the fullest extent
permitted by applicable law, you and the Company will submit solely to final, binding and confidential arbitration any and all
disputes, claims, or causes of action arising from or relating to: (i) the negotiation, execution, interpretation, performance,
breach or enforcement of this Agreement; or (ii) your employment with the Company (including but not limited to all statutory
claims); or (iii) the termination of your employment with the Company (including but not limited to all statutory claims). <B>BY
AGREEING TO THIS ARBITRATION PROCEDURE, BOTH YOU AND THE COMPANY WAIVE THE RIGHT TO RESOLVE ANY SUCH DISPUTES THROUGH A TRIAL BY
JURY OR JUDGE OR THROUGH AN ADMINISTRATIVE PROCEEDING.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>13.2 Arbitrator
Authority</B>. The arbitrator shall have the sole and exclusive authority to determine whether a dispute, claim or cause of action is
subject to arbitration under this Section and to determine any procedural questions which grow out of such disputes, claims or causes
of action and bear on their final disposition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>13.3 Individual
Capacity Only</B>. All claims, disputes, or causes of action under this Section, whether by you or the Company, must be brought solely
in an individual capacity, and shall not be brought as a plaintiff (or claimant) or class member in any purported class or representative
proceeding, nor joined or consolidated with the claims of any other person or entity. The arbitrator may not consolidate the claims of
more than one person or entity, and may not preside over any form of representative or class proceeding. To the extent that the preceding
sentences in this Section are found to violate applicable law or are otherwise found unenforceable, any claim(s) alleged or brought on
behalf of a class shall proceed in a court of law rather than by arbitration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>13.4 Arbitration
Process</B>. Any arbitration proceeding under this Section shall be presided over by a single arbitrator and conducted by Judicial Arbitration
and Mediation Services, Inc. (&ldquo;<B>JAMS</B>&rdquo;) in Boca Raton, Florida, or as otherwise agreed to by you and the Company, under
the then applicable JAMS rules for the resolution of employment disputes (available upon request and also currently available at <U>http://www.jamsadr.com/rules-employment-arbitration/</U>).
You and the Company both have the right to be represented by legal counsel at any arbitration proceeding, at each party&rsquo;s own expense.
The arbitrator shall: (i) have the authority to compel adequate discovery for the resolution of the dispute; (ii) issue a written arbitration
decision, to include the arbitrator&rsquo;s essential findings and conclusions and a statement of the award; and (iii) be authorized to
award any or all remedies that you or the Company would be entitled to seek in a court of law. The Company shall pay all JAMS arbitration
fees in excess of the amount of court fees that would be required of you if the dispute were decided in a court of law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>13.5 Excluded Claims</B>.
This Section shall not apply to any action or claim that cannot be subject to mandatory arbitration as a matter of law, to the extent
such claims are not permitted by applicable law to be submitted to mandatory arbitration and such applicable law is not preempted by the
Federal Arbitration Act or otherwise invalid (collectively, the &ldquo;<B>Excluded Claims</B>&rdquo;). In the event you intend to bring
multiple claims, including one of the Excluded Claims listed above, the Excluded Claims may be filed with a court, while any other claims
will remain subject to mandatory arbitration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>13.6 Injunctive
Relief and Final Orders</B>. Nothing in this Section is intended to prevent either you or the Company from obtaining injunctive relief
in court to prevent irreparable harm pending the conclusion of any such arbitration. Any final award in any arbitration proceeding hereunder
may be entered as a judgment in the federal and state courts of any competent jurisdiction and enforced accordingly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>14.
General Provisions.</B> This Agreement, together with the Confidentiality Agreement, constitutes the entire agreement between you
and the Company with regard to this subject matter and is the complete, final, and exclusive embodiment of the parties&rsquo;
agreement with regard to this subject matter. This Agreement is entered into without reliance on any promise or representation,
written or oral, other than those expressly contained herein, and it supersedes any other such promises, warranties or
representations. Modifications or amendments to this Agreement, other than those changes expressly reserved to the Company&rsquo;s
discretion in this letter, must be made in a written agreement signed by you and the Company&rsquo;s Board. Whenever possible, each
provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable law, but if any
provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any
jurisdiction, such invalidity, illegality or unenforceability will not affect any other provision or any other jurisdiction, but
this Agreement will be reformed, construed and enforced in such jurisdiction to the extent possible in keeping with the intent of
the parties. Any waiver of any breach of any provisions of this Agreement must be in writing to be effective, and it shall not
thereby be deemed to have waived any preceding or succeeding breach of the same or any other provision of this Agreement. This
Agreement is intended to bind and inure to the benefit of and be enforceable by you and the Company, and their respective
successors, assigns, heirs, executors and administrators. The Company may freely assign this Agreement, without your prior written
consent. You may not assign any of your duties hereunder and you may not assign any of your rights hereunder without the written
consent of the Company. The obligations as forth under Sections 8, 9, 10, 11, 12, 13, and 14 will survive the termination of this
Agreement. All questions concerning the construction, validity and interpretation of this Agreement will be governed by the laws of
the State of Florida.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt">This offer is subject to satisfactory
proof of your identity and right to work in the United States and other applicable pre-employment screenings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>[<I>Remainder of page left intentionally blank; signature
page follows]</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">IN WITNESS WHEREOF, the parties hereto have executed this
Agreement as of the date first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IN<FONT STYLE="font-variant: small-caps">mune</FONT>
  B<FONT STYLE="font-variant: small-caps">io</FONT> I<FONT STYLE="font-variant: small-caps">nc</FONT>.</B></FONT></TD>
  <TD STYLE="width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Tim Schroeder</I></FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tim Schroeder</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman of Compensation Committee</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Accepted and agreed:</B></FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ David J.
  Moss</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David J. Moss</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>




<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B><U>Exhibit A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-variant: small-caps"><B>C<FONT STYLE="font-size: 10pt">onfidential</FONT>
i<FONT STYLE="font-size: 10pt">nformation and</FONT> i<FONT STYLE="font-size: 10pt">nvention</FONT> a<FONT STYLE="font-size: 10pt">ssignment</FONT>
a<FONT STYLE="font-size: 10pt">greement</FONT></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">This agreement is made between David
Moss (&ldquo;Employee&rdquo;) and INmune Bio Inc. (the &ldquo;Company&rdquo;) on November 26, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Employee will perform services for the
Company as set forth in the Employment Agreement between the Company and the Employee that may require the Company to disclose confidential
and proprietary information (&ldquo;Confidential Information&rdquo;) to Employee. Confidential Information is information and data of
any kind concerning any matters affecting or relating to the Company, the business or operations of the Company, and/or the products,
drawings, plans, processes, or other data of the Company not generally known or available outside of the company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Accordingly, to protect the Confidential
Information that will be disclosed during employment, the Employee agrees as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: left; margin-top: 0pt; margin-bottom: 0pt">1. Employee will
hold the Confidential Information received from the Company in strict confidence and will exercise a reasonable degree of care to prevent
disclosure to others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: left; margin-top: 0pt; margin-bottom: 0pt">2.
Other than as required in the course of Employee&rsquo;s employment with the Company, the Employee will not disclose or divulge
either directly or indirectly the Confidential Information to others unless first authorized to do so in writing by the
Company&rsquo;s board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: left; margin-top: 0pt; margin-bottom: 0pt">3.
Employee will not reproduce the Confidential Information nor use this information commercially or for any purpose other than the
performance of his duties for the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: left; margin-top: 0pt; margin-bottom: 0pt">4.
Employee will, upon request or upon termination of his/her relationship with the Company, deliver to the Company any drawings,
notes, documents, equipment, and materials received from the Company or originating from employment with the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: left; margin-top: 0pt; margin-bottom: 0pt">5.
The Company will have the sole right to determine the treatment of all inventions, writings, ideas and discoveries received from
Employee during the period of employment with the Company, including the right to keep the same as a trade secret, to use and
disclose the same without prior patent applications, to file copyright registrations in its own name, or to follow any other
procedure as the Company may deem appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: left; margin-top: 0pt; margin-bottom: 0pt">6.
The Company reserves the right to take disciplinary action, up to and including termination, for violations of this agreement in
addition to pursuing civil or criminal penalties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: left; margin-top: 0pt; margin-bottom: 0pt"> 7. This agreement will be interpreted under and governed by the laws of the state of Nevada.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: left; margin-top: 0pt; margin-bottom: 0pt">8.
All provisions of this agreement will be applicable only to the extent that they do not violate any applicable law and are intended
to be limited to the extent necessary so that they will not render this agreement invalid, illegal or unenforceable. If any
provision of this agreement or any application thereof will be held to be invalid, illegal or unenforceable, the validity, legality
and enforceability of other provisions of this agreement or of any other application of such provision will in no way be affected
thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Immunity from Liability for Confidential Disclosure of a Trade
Secret to the Government or in a Court Filing:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">(1) Immunity&mdash;An
individual will not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret
that (A) is made (i) in confidence to a federal, state or local government official, either directly or indirectly, or to an attorney
and (ii) solely for the purpose of reporting or investigating a suspected violation of law or (B) is made in a complaint or other document
filed in a lawsuit or other proceeding, if such filing is made under seal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">(2) Use
of Trade Secret Information in Anti-Retaliation Lawsuit&mdash;An individual who files a lawsuit for retaliation by an employer for reporting
a suspected violation of law may disclose the trade secret to the attorney of the individual and use the trade secret information in the
court proceeding, if the individual (A) files any document containing the trade secret under seal and (B) does not disclose the trade
secret, except pursuant to court order.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Employee represents and warrants that he or she is not under
any pre-existing obligations inconsistent with the provisions of this agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Signing below signifies that the Employee agrees to the terms
and conditions of the agreement stated above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employee:</FONT></TD>
    <TD STYLE="width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INmune Bio Inc.:</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ David
    Moss</I></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ J.
    Kelly Ganjei</I></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David Moss</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">J. Kelly Ganjei, Chairman</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>ea026754601ex10-2_inmune.htm
<DESCRIPTION>EMPLOYMENT AGREEMENT, DATED NOVEMBER 26, 2025, BETWEEN INMUNE BIO INC. AND CORY ELLSPERMANN
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>INmune Bio Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>225 NE Mizner Blvd., Suite 640</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Boca Raton, Florida 33432</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">November 26, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Cory Ellspermann</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Re:</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Offer of Employment</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Dear Mr. Ellspermann:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: left; margin-top: 0pt; margin-bottom: 0pt">INmune Bio Inc. (the &ldquo;<B>Company</B>&rdquo;)
is pleased to offer you continued at-will employment in the position of Chief Financial Officer on the terms and conditions set forth
in this letter agreement (the &ldquo;<B>Agreement</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><B>1. Employment
by the Company.</B> Your employment with the Company shall continue on these terms effective as of November 1, 2025, or such date as otherwise
agreed to by you and the Company (such actual date your employment begins on these terms, the (&ldquo;<B>Effective Date</B>&rdquo;)).
This is an exempt position, and during your employment with the Company, you will devote your best efforts and substantially all of your
business time and attention to the business of the Company, except for approved vacation periods and reasonable periods of illness or
other incapacities permitted by the Company&rsquo;s general employment policies. You shall perform such duties as are required by the
Company&rsquo;s Board of Directors (&ldquo;<B>Board</B>&rdquo;), to whom you will report. The Company reserves the right to reasonably require you to perform your duties at places other than
your primary office location from time to time, and to require reasonable business travel. The Company may modify your job title and duties
as it deems necessary and appropriate in light of the Company&rsquo;s needs and interests from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"> <B>2.</B> <B>Compensation.</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>2.1 Base Salary.</B>
For services to be rendered hereunder, you shall receive a base salary at the rate of $275,000 per year (the &ldquo;<B>Base Salary</B>&rdquo;),
subject to standard payroll deductions and withholdings and payable in accordance with the Company&rsquo;s regular payroll schedule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>2.2
Annual Bonus.</B> You will be eligible for an annual discretionary bonus with a target amount of 40% of your then current annual
Base Salary, prorated for the number of days employed in a calendar year (the &ldquo;<B>Annual Bonus</B>&rdquo;). Whether you
receive an Annual Bonus for any given year, and the amount of any such Annual Bonus, will be determined by the Board and/or its
Compensation Committee in its discretion based upon the achievement of corporate and/or individual objectives and milestones that
are determined in the sole discretion of the Board. If your employment terminates for any reason prior to the date such Annual
Bonus, if any, is paid, then you will not have earned an Annual Bonus for that year and will not receive any portion of it, except
as provided in Section 8. The Annual Bonus, if earned, shall be paid to you in a lump sum no later than March 15<FONT STYLE="font-size: 10pt"><SUP>th</SUP></FONT>
of the calendar year that follows the performance year, subject to applicable payroll deductions and withholdings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>2.3 Equity</B>.
Subject to approval by the Board, you shall be granted an option to purchase 300,000 shares of common stock of the Company (the &ldquo;<B>Option</B>&rdquo;)
pursuant to the Second Amended and Restated INmune Bio Inc. 2021 Stock Incentive Plan. (as amended from time to time, the &ldquo;<B>Plan</B>&rdquo;).
The exercise price of the Option shall be the minimum permissible amount, and such exercise price as well as all other matters related
to the Option, will be governed by and subject to the terms and conditions set forth in the Plan, and the stock option agreement you will
be required to execute. Upon a Change of Control (as defined in the Plan), the vesting and exercisability of all unvested shares subject
to the Option shall accelerate and become immediately vested and exercisable as of the date of the closing of the Change of Control (the
&ldquo;<B>CIC Equity Acceleration</B>&rdquo;). The CIC Equity Acceleration shall be subject to your Continuous Service (as defined in
the Plan) up to and including the closing date of such Change of Control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><B>3. Reasonable
Business Expenses.</B> You will be eligible for reimbursement of all reasonable, necessary and documented out-of-pocket business, entertainment,
and travel expenses incurred by you in connection with the performance of your duties hereunder in accordance with the Company&rsquo;s
expense reimbursement policies and procedures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><B>4. Paid
Time Off; Holidays.</B> You will initially be eligible to accrue up to [three weeks] of paid time off during each calendar year, subject
to applicable maximum accrual caps, in accordance with the Company&rsquo;s paid time off policies as in effect from time to time. You
will also be eligible for certain paid holidays pursuant to Company policy. The Company reserves the right to cancel or change its policies
regarding paid time off, paid sick leave and/or holidays from time to time without amendment of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><B>5.
Company Policies; Standard Company Benefits</B>. The employment relationship between the parties shall be governed by the general
employment policies and practices of the Company, except that when the terms of this Agreement differ from or are in conflict with
the Company&rsquo;s general employment policies or practices, this Agreement shall control. You shall be entitled to participate in
all employee benefit programs for which you are eligible under the terms and conditions of the benefit plans that may be in effect
from time to time and provided by the Company to its employees. The Company reserves the right to cancel or change the benefit plans
or programs it offers to its employees at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><B>6.
At-Will Employment.</B> Your employment relationship is at-will. Either you or the Company may terminate the employment relationship
at any time, with or without cause or advance notice. Upon termination of your employment for any reason, you shall resign from all
positions and terminate any relationships as an employee, advisor, officer or director with the Company and any of its affiliates,
each effective on the date of termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><B>7.
Outside Activities During Employment.</B> Except with the prior written consent of the Board, you will not during the term of your
employment with the Company undertake or engage in any other employment, occupation or business enterprise, other than ones in which
you are a passive investor. You may engage in civic and not-for-profit activities and be a member of the board of directors of other
companies so long as such activities do not materially interfere with the performance of your duties hereunder and such other
companies are not competitive with the Company&rsquo;s business. You agree not to acquire, assume or participate in, directly or
indirectly, any position, material investment or interest known to be adverse or antagonistic to the Company, its business or
prospects, financial or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B></B></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: left; margin-top: 0pt; margin-bottom: 0pt"> <B>8.</B> <B>Termination; Severance.</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>8.1 Compensation
upon Termination.</B> Upon the termination of your employment for any reason, the Company shall pay you all of your accrued and unpaid
wages earned through your last day of employment (the &ldquo;<B>Separation Date</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>8.2 Involuntary
Termination.</B> If you are subject to an Involuntary Termination (as defined below), and provided that you remain in compliance with
the terms of this Agreement (including the conditions described in <U>Section 8.4</U> below), the Company shall provide you with the following
benefits (the &ldquo;<B>Severance Benefits</B>&rdquo;):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>(a)
Cash Severance.</B> The Company shall pay you, as severance, the equivalent of 18 months (the &ldquo;<B>Severance Period</B>&rdquo;)
of your Base Salary in effect as of the Separation Date, subject to standard payroll deductions and withholdings. The Severance will
be paid as a continuation on the Company&rsquo;s regular payroll, beginning no later than the first regularly-scheduled payroll date
following the sixtieth (60<FONT STYLE="font-size: 10pt"><SUP>th</SUP></FONT>) day after your Separation from Service, provided the
Separation Agreement (as discussed in <U>Section 8.4</U>) has become effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>(b) Prorated
Annual Bonus.</B> You will be eligible to receive a prorated Annual Bonus (calculated as the Annual Bonus that would have been paid for
the entire calendar year multiplied by a fraction, the numerator of which is equal to the number of days you worked in the applicable
calendar year, and the denominator of which is equal to the total number of days in such year). The prorated Annual Bonus, if any, will
be paid to you, subject to standard payroll deductions and withholdings, at the time such bonus is paid to similarly situated employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>(c)
Payment of Continued Group Health Plan Benefits.</B> If you are eligible for and timely elect continued group health plan coverage
under the Consolidated Omnibus Budget Reconciliation Act of 1985 or any state law of similar effect (&ldquo;<B>COBRA</B>&rdquo;)
following your Involuntary Termination, the Company will pay your COBRA group health insurance premiums or equivalent of COBRA if
the company is not eligible for COBRA for you and your eligible dependents directly to the insurer until the earliest of (A) the end
of the period immediately following your Involuntary Termination that is equal to the Severance Period (the &ldquo;<B>COBRA Payment
Period</B>&rdquo;), (B) the expiration of your eligibility for continuation coverage under COBRA, or (C) the date when you become
eligible for substantially equivalent health insurance coverage in connection with new employment or self-employment. For purposes
of this Section, references to COBRA premiums shall not include any amounts payable by you under a Section 125 health care
reimbursement plan under the Code. Notwithstanding the foregoing, if at any time the Company determines, in its sole discretion,
that it cannot pay the COBRA premiums without potentially incurring financial costs or penalties under applicable law (including,
without limitation, Section 2716 of the Public Health Service Act), then regardless of whether you elect continued health coverage
under COBRA, and in lieu of providing the COBRA premiums, the Company will instead pay you on the last day of each remaining month
of the COBRA Payment Period, a fully taxable cash payment equal to the COBRA premiums for that month, subject to applicable tax
withholdings (such amount, the &ldquo;<B>Special Severance Payment</B>&rdquo;), which payments shall continue until the earlier of
expiration of the COBRA Payment Period or the date when you become eligible for substantially equivalent health insurance coverage
in connection with new employment or self-employment. On the first payroll date following the effectiveness of the Separation
Agreement, the Company will make the first payment to the insurer under this clause (and, in the case of the Special Severance
Payment, such payment will be to you, in a lump sum) equal to the aggregate amount of payments that the Company would have paid
through such date had such payments instead commenced on the Separation Date, with the balance of the payments paid thereafter on
the schedule described above. If you become eligible for coverage under another employer&rsquo;s group health plan, you must
immediately notify the Company of such event, and all payments and obligations under this subsection shall cease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>8.3 Termination
for Cause; Resignation Without Good Reason; Death or Disability.</B> If you resign without Good Reason, or the Company terminates your
employment for Cause, upon dissolution or cessation of the Company, or upon your death or disability, then (a) you will no longer vest
in the Option, (b) all payments of compensation by the Company to you hereunder will terminate immediately (except as to amounts already
earned), and (c) you will not be entitled to any Severance Benefits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>8.4 Conditions to
Receipt of Severance Benefits.</B> The receipt of the Severance Benefits will be subject to you signing and not revoking a separation
agreement and general release of claims in a form reasonably satisfactory to the Company (the &ldquo;<B>Separation Agreement</B>&rdquo;)
by no later than the sixtieth (60th) day after the Separation Date (&ldquo;<B>Release Deadline</B>&rdquo;). No Severance Benefits will
be paid or provided until the Separation Agreement becomes effective. You shall also resign from all positions and terminate any relationships
as an employee, advisor, officer or director with the Company and any of its affiliates, each effective on the Separation Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"><B>9. Definitions.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>9.1 Cause.</B> For
purposes of this Agreement, <B>&ldquo;Cause&rdquo;</B> for termination means: (a) commission of any felony or crime involving dishonesty;
(b) participation in any fraud against the Company; (c) material breach of your duties to the Company; (d) persistent unsatisfactory performance
of job duties after written notice from the Board and an opportunity to cure (if deemed curable by the Company in its sole discretion);
(e) intentional damage to any material property of the Company; (f) misconduct, or other violation of Company policy that causes material
harm; (g) breach of this Agreement, the Confidentiality Agreement (as defined below), or any other written agreement with the Company;
or (h) conduct by you which in the good faith and reasonable determination of the Board demonstrates gross unfitness to serve.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>9.2 Code.</B> For
purposes of this Agreement, <B>&ldquo;Code&rdquo;</B> means the U.S. Internal Revenue Code of 1986 (as it has been and may be amended
from time to time) and any regulations and guidance that has been promulgated or may be promulgated from time to time thereunder and any
state law of similar effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>9.3
Good Reason.</B> For purposes of this Agreement, you shall have &ldquo;<B>Good Reason</B>&rdquo; for resignation from employment
with the Company if any of the following actions are taken by the Company without your prior written consent: (a) a material
reduction in your Base Salary, which the parties agree is a reduction of at least 10% of your Base Salary (unless pursuant to a
salary reduction program applicable generally to the Company&rsquo;s similarly situated employees); (b) a material reduction in your
duties (including responsibilities and/or authorities), <I>provided, however,</I> that a change in job position (including a change
in title) shall not be deemed a &ldquo;material reduction&rdquo; in and of itself unless your new duties are materially reduced from
the prior duties; or (c) relocation of your principal place of employment to a place that increases your one-way commute by more
than fifty (50) miles as compared to your then-current principal place of employment immediately prior to such relocation. In order
to resign for Good Reason, you must provide written notice to the Company&rsquo;s Board within 30 days after the first occurrence of
the event giving rise to Good Reason setting forth the basis for your resignation, allow the Company at least 30 days from receipt
of such written notice to cure such event, and if such event is not reasonably cured within such period, you must resign from all
positions you then hold with the Company not later than 90 days after the expiration of the cure period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>9.4 Involuntary
Termination.</B> For purposes of this Agreement, &ldquo;<B>Involuntary Termination</B>&rdquo; means a termination of your employment with
the Company pursuant to either (i) a termination initiated by the Company without Cause, or (ii) your resignation for Good Reason, and
provided in either case such termination constitutes a Separation from Service. An Involuntary Termination does not include any other
termination of your employment, including a termination due to your death or disability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>9.5 Separation from
Service.</B> For purposes of this Agreement, &ldquo;Separation from Service&rdquo; means a &ldquo;separation from service&rdquo;, as defined
under Treasury Regulation Section 1.409A-1(h).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>10.
Proprietary Information Obligations.</B> As a condition of your continued employment, you shall continue to abide by the
Company&rsquo;s standard form of Confidential Information and Invention Assignment Agreement (the &ldquo;<B>Confidentiality
Agreement</B>&rdquo;), attached as <B><U>Exhibit A</U></B>. In your work for the Company, you will be expected not to use or
disclose any confidential information, including trade secrets, of any former employer or other person to whom you have an
obligation of confidentiality. Rather, you will be expected to use only that information which is generally known and used by
persons with training and experience comparable to your own, which is common knowledge in the industry or otherwise legally in the
public domain, or which is otherwise provided or developed by the Company. You agree that you will not bring onto Company premises
any unpublished documents or property belonging to any former employer or other person to whom you have an obligation of
confidentiality. You hereby represent that you have disclosed to the Company any contract you have signed that may restrict your
activities on behalf of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>11.
Section 409A.</B> It is intended that all of the severance benefits and other payments payable under this Agreement satisfy, to the
greatest extent possible, the exemptions from the application of Code Section 409A provided under Treasury Regulations Sections
1.409A 1(b)(4), 1.409A 1(b)(5) and 1.409A 1(b)(9), and this Agreement will be construed to the greatest extent possible as
consistent with those provisions, and to the extent not so exempt, this Agreement (and any definitions hereunder) will be construed
in a manner that complies with Section 409A. For all purposes of Code Section 409A (including, without limitation, for purposes of
Treasury Regulations Sections 1.409A 2(b)(2)(i) and (iii)), your right to receive any installment payments under this Agreement
(whether severance payments, reimbursements or otherwise) shall be treated as a right to receive a series of separate payments and,
accordingly, each installment payment hereunder shall at all times be considered a separate and distinct payment. Notwithstanding
any provision to the contrary in this Agreement, if you are deemed by the Company at the time of your Separation from Service to be
a &ldquo;specified employee&rdquo; for purposes of Code Section 409A(a)(2)(B)(i), and if any of the payments upon Separation from
Service set forth herein and/or under any other agreement with the Company are deemed to be &ldquo;deferred compensation,&rdquo;
then to the extent delayed commencement of any portion of such payments is required in order to avoid a prohibited distribution
under Code Section 409A(a)(2)(B)(i) and the related adverse taxation under Section 409A, such payments shall not be provided to you
prior to the earliest of (i) the first date following expiration of the six-month period following the date of your Separation from
Service with the Company, (ii) the date of your death or (iii) such earlier date as
permitted under Section 409A without the imposition of adverse taxation. Upon the first business day following the expiration of
such applicable Code Section 409A(a)(2)(B)(i) period, all payments deferred pursuant to this Paragraph shall be paid in a lump sum
to you, and any remaining payments due shall be paid as otherwise provided herein or in the applicable agreement. No interest shall
be due on any amounts so deferred. If the severance benefits are not covered by one or more exemptions from the application of
Section 409A and the Release Deadline occurs in the calendar year following the calendar year of your Separation from Service, the
Separation Agreement will not be deemed effective any earlier than the Release Deadline for purposes of determining the timing of
provision of any severance benefits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>12. Section 280G.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: left">If any payment or
benefit you will or may receive from the Company or otherwise (a &ldquo;<B>280G Payment</B>&rdquo;) would (i) constitute a &ldquo;parachute
payment&rdquo; within the meaning of Section 280G of the Code, and (ii) but for this sentence, be subject to the excise tax imposed by
Section 4999 of the Code (the &ldquo;<B>Excise Tax</B>&rdquo;), then any such 280G Payment pursuant to this Agreement or otherwise (a
&ldquo;<B>Payment</B>&rdquo;) shall be equal to the Reduced Amount. The &ldquo;<B>Reduced Amount</B>&rdquo; shall be either (x) the largest
portion of the Payment that would result in no portion of the Payment (after reduction) being subject to the Excise Tax or (y) the largest
portion, up to and including the total, of the Payment, whichever amount (i.e., the amount determined by clause (x) or by clause (y)),
after taking into account all applicable federal, state and local employment taxes, income taxes, and the Excise Tax (all computed at
the highest applicable marginal rate), results in your receipt, on an after-tax basis, of the greater economic benefit notwithstanding
that all or some portion of the Payment may be subject to the Excise Tax. If a reduction in a Payment is required pursuant to the preceding
sentence and the Reduced Amount is determined pursuant to clause (x) of the preceding sentence, the reduction shall occur in the manner
(the &ldquo;<B>Reduction Method</B>&rdquo;) that results in the greatest economic benefit for you. If more than one method of reduction
will result in the same economic benefit, the items so reduced will be reduced pro rata (the &ldquo;<B>Pro Rata Reduction Method</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Notwithstanding the
foregoing, if the Reduction Method or the Pro Rata Reduction Method would result in any portion of the Payment being subject to taxes
pursuant to Section 409A that would not otherwise be subject to taxes pursuant to Section 409A, then the Reduction Method and/or the Pro
Rata Reduction Method, as the case may be, shall be modified so as to avoid the imposition of taxes pursuant to Section 409A as follows:
(A) as a first priority, the modification shall preserve to the greatest extent possible, the greatest economic benefit for you as determined
on an after-tax basis; (B) as a second priority, Payments that are contingent on future events (e.g., being terminated without Cause),
shall be reduced (or eliminated) before Payments that are not contingent on future events; and (C) as a third priority, Payments that
are &ldquo;deferred compensation&rdquo; within the meaning of Section 409A shall be reduced (or eliminated) before Payments that are not
deferred compensation within the meaning of Section 409A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Unless you and the
Company agree on an alternative accounting firm, the accounting firm engaged by the Company for general tax compliance purposes as of
the day prior to the effective date of the change in control transaction triggering the Payment shall perform the foregoing calculations.
If the accounting firm so engaged by the Company is serving as accountant or auditor for the individual, entity or group effecting the
change in control transaction, the Company shall appoint a nationally recognized accounting firm to make the determinations required hereunder.
The Company shall bear all expenses with respect to the determinations by such accounting firm required to be made hereunder. The Company
shall use commercially reasonable efforts to cause the accounting firm engaged to make the determinations hereunder to provide its calculations,
together with detailed supporting documentation, to you and the Company within fifteen (15) calendar days after the date on which your
right to a 280G Payment becomes reasonably likely to occur (if requested at that time by you or the Company) or such other reasonable
time as requested by you or the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: left">If you receive a
Payment for which the Reduced Amount was determined pursuant to clause (x) of the first paragraph of this Section and the Internal Revenue
Service determines thereafter that some portion of the Payment is subject to the Excise Tax, you shall promptly return to the Company
a sufficient amount of the Payment (after reduction pursuant to clause (x) of the first paragraph of this Section so that no portion of
the remaining Payment is subject to the Excise Tax). For the avoidance of doubt, if the Reduced Amount was determined pursuant to clause
(y) in the first paragraph of this Section, you shall have no obligation to return any portion of the Payment pursuant to the preceding
sentence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>13. Arbitration of All Disputes.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>13.1
Agreement to Arbitrate</B>. To ensure the timely and economical resolution of disputes that may arise between you and the Company,
both you and the Company mutually agree that pursuant to the Federal Arbitration Act, 9 U.S.C. &sect;1-16, and to the fullest extent
permitted by applicable law, you and the Company will submit solely to final, binding and confidential arbitration any and all
disputes, claims, or causes of action arising from or relating to: (i) the negotiation, execution, interpretation, performance,
breach or enforcement of this Agreement; or (ii) your employment with the Company (including but not limited to all statutory
claims); or (iii) the termination of your employment with the Company (including but not limited to all statutory claims). <B>BY
AGREEING TO THIS ARBITRATION PROCEDURE, BOTH YOU AND THE COMPANY WAIVE THE RIGHT TO RESOLVE ANY SUCH DISPUTES THROUGH A TRIAL BY
JURY OR JUDGE OR THROUGH AN ADMINISTRATIVE PROCEEDING.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>13.2 Arbitrator
Authority</B>. The arbitrator shall have the sole and exclusive authority to determine whether a dispute, claim or cause of action is
subject to arbitration under this Section and to determine any procedural questions which grow out of such disputes, claims or causes
of action and bear on their final disposition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>13.3 Individual
Capacity Only</B>. All claims, disputes, or causes of action under this Section, whether by you or the Company, must be brought solely
in an individual capacity, and shall not be brought as a plaintiff (or claimant) or class member in any purported class or representative
proceeding, nor joined or consolidated with the claims of any other person or entity. The arbitrator may not consolidate the claims of
more than one person or entity, and may not preside over any form of representative or class proceeding. To the extent that the preceding
sentences in this Section are found to violate applicable law or are otherwise found unenforceable, any claim(s) alleged or brought on
behalf of a class shall proceed in a court of law rather than by arbitration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>13.4
Arbitration Process</B>. Any dispute, controversy, or claim arising out of or related to this Agreement or any breach of this Agreement
or your employment, whether the claim arises in contract, tort, or statute, shall be submitted to and decided by binding arbitration.
Arbitration shall be administered exclusively by Judicial Arbitration and Mediation Services, Inc. (&ldquo;<B>JAMS</B>&rdquo;) in Boca
Raton, Florida, or as otherwise agreed to by you and the Company, under the then applicable JAMS rules for the resolution of employment
disputes (available upon request and also currently available at</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">http://www.jamsadr.com/rules-employment-arbitration/)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">.
Any arbitral award determination shall be final and binding upon the parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>13.5 Injunctive
Relief and Final Orders</B>. Nothing in this Section is intended to prevent either you or the Company from obtaining injunctive relief
in court to prevent irreparable harm pending the conclusion of any such arbitration. Any final award in any arbitration proceeding hereunder
may be entered as a judgment in the federal and state courts of any competent jurisdiction and enforced accordingly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>14.
General Provisions.</B> This Agreement, together with the Confidentiality Agreement, constitutes the entire agreement between you
and the Company with regard to this subject matter and is the complete, final, and exclusive embodiment of the parties&rsquo;
agreement with regard to this subject matter. This Agreement is entered into without reliance on any promise or representation,
written or oral, other than those expressly contained herein, and it supersedes any other such promises, warranties or
representations. Modifications or amendments to this Agreement, other than those changes expressly reserved to the Company&rsquo;s
discretion in this letter, must be made in a written agreement signed by you and the Company&rsquo;s Board. Whenever possible, each
provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable law, but if any
provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any
jurisdiction, such invalidity, illegality or unenforceability will not affect any other provision or any other jurisdiction, but
this Agreement will be reformed, construed and enforced in such jurisdiction to the extent possible in keeping with the intent of
the parties. Any waiver of any breach of any provisions of this Agreement must be in writing to be effective, and it shall not
thereby be deemed to have waived any preceding or succeeding breach of the same or any other provision of this Agreement. This
Agreement is intended to bind and inure to the benefit of and be enforceable by you and the Company, and their respective
successors, assigns, heirs, executors and administrators. The Company may freely assign this Agreement, without your prior written
consent. You may not assign any of your duties hereunder and you may not assign any of your rights hereunder without the written
consent of the Company. The obligations as forth under Sections 8, 9, 10, 11, 12, 13, and 14 will survive the termination of this
Agreement. All questions concerning the construction, validity and interpretation of this Agreement will be governed by the laws of
the State of Florida.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt">This offer is subject to satisfactory
proof of your identity and right to work in the United States and other applicable pre-employment screenings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>[<I>Remainder of page left intentionally blank; signature
page follows]</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">IN WITNESS WHEREOF, the parties hereto have executed this
Agreement as of the date first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IN<FONT STYLE="font-variant: small-caps">mune</FONT>
  B<FONT STYLE="font-variant: small-caps">io</FONT> I<FONT STYLE="font-variant: small-caps">nc</FONT>.</B></FONT></TD>
  <TD STYLE="width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Tim Schroeder</I></FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tim Schroeder</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman of Compensation Committee</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Accepted and agreed:</B></FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Cory Ellspermann</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cory Ellspermann</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>Exhibit A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-variant: small-caps"><B>C<FONT STYLE="font-size: 10pt">onfidential</FONT>
i<FONT STYLE="font-size: 10pt">nformation and</FONT> i<FONT STYLE="font-size: 10pt">nvention</FONT> a<FONT STYLE="font-size: 10pt">ssignment</FONT>
a<FONT STYLE="font-size: 10pt">greement</FONT></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">This agreement is made between Cory Ellspermann
(&ldquo;Employee&rdquo;) and INmune Bio Inc. (the &ldquo;Company&rdquo;) on November 26, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Employee will perform services for the
Company as set forth in the Employment Agreement between the Company and the Employee that may require the Company to disclose confidential
and proprietary information (&ldquo;Confidential Information&rdquo;) to Employee. Confidential Information is information and data of
any kind concerning any matters affecting or relating to the Company, the business or operations of the Company, and/or the products,
drawings, plans, processes, or other data of the Company not generally known or available outside of the company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Accordingly, to protect the Confidential
Information that will be disclosed during employment, the Employee agrees as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: left; margin-top: 0pt; margin-bottom: 0pt">1. Employee will
hold the Confidential Information received from the Company in strict confidence and will exercise a reasonable degree of care to prevent
disclosure to others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: left; margin-top: 0pt; margin-bottom: 0pt">2. Other
than as required in the course of Employee&rsquo;s employment with the Company, the Employee will not disclose or divulge either directly
or indirectly the Confidential Information to others unless first authorized to do so in writing by the Company&rsquo;s board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: left; margin-top: 0pt; margin-bottom: 0pt">3. Employee will
not reproduce the Confidential Information nor use this information commercially or for any purpose other than the performance of his
duties for the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: left; margin-top: 0pt; margin-bottom: 0pt">4. Employee
will, upon request or upon termination of his/her relationship with the Company, deliver to the Company any drawings, notes, documents,
equipment, and materials received from the Company or originating from employment with the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: left; margin-top: 0pt; margin-bottom: 0pt">5. The
Company will have the sole right to determine the treatment of all inventions, writings, ideas and discoveries received from Employee
during the period of employment with the Company, including the right to keep the same as a trade secret, to use and disclose the same
without prior patent applications, to file copyright registrations in its own name, or to follow any other procedure as the Company may
deem appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: left; margin-top: 0pt; margin-bottom: 0pt">6. The Company reserves
the right to take disciplinary action, up to and including termination, for violations of this agreement in addition to pursuing civil
or criminal penalties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: left; margin-top: 0pt; margin-bottom: 0pt"> 7. This agreement will be interpreted under and governed by the laws of the state of Nevada.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: left; margin-top: 0pt; margin-bottom: 0pt">8. All
provisions of this agreement will be applicable only to the extent that they do not violate any applicable law and are intended to be
limited to the extent necessary so that they will not render this agreement invalid, illegal or unenforceable. If any provision of this
agreement or any application thereof will be held to be invalid, illegal or unenforceable, the validity, legality and enforceability of
other provisions of this agreement or of any other application of such provision will in no way be affected thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Immunity from Liability for Confidential Disclosure of a Trade
Secret to the Government or in a Court Filing:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">(1) Immunity&mdash;An
individual will not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret
that (A) is made (i) in confidence to a federal, state or local government official, either directly or indirectly, or to an attorney
and (ii) solely for the purpose of reporting or investigating a suspected violation of law or (B) is made in a complaint or other document
filed in a lawsuit or other proceeding, if such filing is made under seal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">(2) Use
of Trade Secret Information in Anti-Retaliation Lawsuit&mdash;An individual who files a lawsuit for retaliation by an employer for reporting
a suspected violation of law may disclose the trade secret to the attorney of the individual and use the trade secret information in the
court proceeding, if the individual (A) files any document containing the trade secret under seal and (B) does not disclose the trade
secret, except pursuant to court order.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Employee represents and warrants that he or she is not under
any pre-existing obligations inconsistent with the provisions of this agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Signing below signifies that the Employee agrees to the terms
and conditions of the agreement stated above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employee:</FONT></TD>
    <TD STYLE="width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INmune Bio Inc.:</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Cory
    Ellspermann</I></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ J.
    Kelly Ganjei</I></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cory Ellspermann</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">J. Kelly Ganjei, Chairman</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>ea026754601ex10-3_inmune.htm
<DESCRIPTION>EMPLOYMENT AGREEMENT, DATED NOVEMBER 26, 2025, BETWEEN INMUNE BIO INTERNATIONAL LIMITED AND MARK LOWDELL
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.3</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EMPLOYMENT
AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INmune
Bio International Limited</B><BR>
(Company No. 10105962)<BR>
48 Chancery Lane<BR>
London, WC2A 1JF<BR>
(the &ldquo;Company&rdquo;)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>and</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Mark
Lowdell, PhD</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(the
&ldquo;Employee&rdquo;)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Effective
Date:</B> 1 November 2025</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.
Position and Duties</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<B>Title and Role.</B> You are employed as Chief Scientific Officer of the Company. This position also includes serving as the Chief
Scientific Officer of INmune Bio Inc., the parent company of the Company. You shall report to the Company&rsquo;s Board of Directors
or such person as the Board may designate. Your duties will include the scientific and strategic leadership of the Company&rsquo;s programmes,
including but not limited to the cell-medicine programmes, including research and development, pre-clinical, clinical, chemistry-manufacturing-controls
(CMC) and related development functions, and such other duties as may reasonably be assigned from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<B>Place of Work.</B> Your normal place of work will be the Company&rsquo;s office in the Stevenage, UK area. You may be required to
work remotely or to travel within the United Kingdom or abroad (including to the United States) as reasonably necessary for the performance
of your duties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<B>Secondment to Parent Company.</B> You will remain an employee of INmune Bio International Limited and will also perform services for
INmune Bio Inc. (USA) under which a secondment arrangement may be required if such duties exceed reasonable time commitments. All remuneration
and benefits will be paid solely by the UK entity, which shall recharge costs to its parent as appropriate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<B>Obligations to the Company.</B> During your employment you shall devote your full business time, attention and abilities to the business
of the Company, comply with all Company policies and not, without prior written consent, undertake other paid employment or consultancy.
You may, however, participate in charitable, civic, or academic activities provided these do not conflict with your duties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<B>No Conflicting Obligations.</B> You confirm that you are not bound by any existing agreement or obligation which would conflict with
your employment hereunder and that you have returned all property and confidential information belonging to any prior employer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.
Working Hours</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Your
normal working hours are 37.5 hours per week, Monday to Friday.<BR></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>You
agree that the 48-hour weekly working limit under the Working Time Regulations 1998 shall not apply to your employment. You may withdraw
this opt-out by giving three months&rsquo; written notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.
Salary and Bonus</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<B>Base Salary.</B> Your gross base salary is &pound;25,000 per month (&pound;300,000 per annum), payable monthly in arrears on or about
the last working day of each month by bank transfer, subject to deductions required by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<B>Review.</B> Your Base Salary will be reviewed periodically by the Board or its Compensation Committee but the Company is not obliged
to increase it.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<B>Bonus.</B> You will be eligible to be considered for an annual discretionary bonus of up to 20 percent of Base Salary, dependent on
individual and Company performance criteria set by the Board. You must be in employment and not under notice at the payment date to be
eligible.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.
Benefits</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<B>Pension.</B> You will be automatically enrolled into the Company&rsquo;s pension scheme in accordance with the Pensions Act 2008.
Details of the scheme and your rights to opt out will be provided separately.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<B>Sick Pay.</B> You will be entitled to Statutory Sick Pay (SSP) in accordance with UK law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<B>Other Benefits.</B> You will be eligible to participate in benefit plans generally available to senior employees, subject to plan
rules and the Company&rsquo;s discretion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.
Holiday</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
are entitled to 25 working days paid holiday per holiday year, 1 January to 31 December, in addition to the usual public holidays in
England and Wales. Holiday accrues pro rata during the first and last years of employment. Unused holiday may not be carried forward
or paid in lieu except as required by law or approved by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.
Business Expenses</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company will reimburse you for all reasonable business expenses properly incurred in the performance of your duties, in accordance with
the Company&rsquo;s expense-reimbursement policy and upon provision of appropriate documentation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7.
Confidentiality and Intellectual Property</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Your
obligations concerning confidentiality, inventions and intellectual-property ownership are set out in Attachment A &ndash; Confidential
Information and Invention Assignment Agreement, which forms part of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.
Termination</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<B>Notice Period.</B> Either party may terminate your employment by giving not less than three (3) months&rsquo; written notice, or payment
in lieu of notice by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<B>Summary Dismissal.</B> The Company may terminate your employment without notice or payment in lieu for gross misconduct or other circumstances
entitling summary dismissal under English law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<B>Termination on Death or Permanent Disability.</B> Employment shall terminate automatically upon death or upon your inability to perform
the essential functions of your position, with or without reasonable accommodation, for a period of 90 consecutive days due to physical
or mental impairment (&ldquo;Permanent Disability&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<B>Obligations on Termination.</B> Upon termination you must return all Company property and comply with your continuing obligations
of confidentiality.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>9.
Severance</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Company terminates your employment for any reason other than Cause, death or Permanent Disability, you shall receive severance pay
equal to 18 months of Base Salary, payable in accordance with normal payroll cycles and subject to statutory deductions. Such severance
payments are inclusive of any statutory or contractual notice pay, redundancy pay or other termination entitlements. Receipt of severance
is conditional upon your execution (without revocation) of a full release of claims in the Company&rsquo;s standard form.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
these purposes, &ldquo;Cause&rdquo; means gross misconduct or other circumstances entitling the Company to dismiss you without notice
under English law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10.
Grievance and Disciplinary Procedures</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s disciplinary and grievance procedures apply to your employment. Copies are available in the Company&rsquo;s Employee
Handbook or from Human Resources. These procedures are non-contractual and may be amended by the Company from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.
Indemnification</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company shall indemnify you to the maximum extent permitted by applicable law and its articles of association and shall maintain directors&rsquo;
and officers&rsquo; liability insurance covering you while you serve the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12.
Data Protection</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Your
personal data will be processed by the Company in accordance with its Data Protection Policy and the UK GDPR for employment-related purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>13.
Entire Agreement and Miscellaneous</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
This Agreement (including Attachment A) constitutes the entire understanding between the parties and supersedes all prior oral or written
agreements relating to your employment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
No amendment or waiver shall be effective unless in writing and signed by both parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
This Agreement and any dispute or claim arising from it shall be governed by and construed in accordance with the laws of England and
Wales, and the parties submit to the exclusive jurisdiction of the courts of England and Wales.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
If any provision of this Agreement is found invalid or unenforceable, it shall be deemed amended to the minimum extent necessary to comply
with law, and the remainder shall remain in full force and effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
This Agreement may be executed in counterparts, each of which shall constitute an original but together one instrument.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>14.
Acknowledgement and Acceptance</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Please
sign and date below to indicate your acceptance of the terms of employment set out herein and return one fully executed copy to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><B>For and on behalf of INmune Bio International Limited</B></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><B>Accepted and Agreed by:</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">Signature:&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 42%">/s/ David Moss</TD>
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="width: 5%">Signature:&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 42%">/s/ Mark Lowdell</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Name:</TD>
    <TD><B>David Moss</B></TD>
    <TD>&nbsp;</TD>
    <TD>Name:</TD>
    <TD><B>Mark Lowdell, PhD</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Title:</TD>
    <TD>UK Director &amp; Company CEO</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">Date: November 26, 2025</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">Date: November 26, 2025</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>




<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>Attachment A:</B> Confidential
Information and Invention Assignment Agreement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>ATTACHMENT A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>INmune Bio EMPLOYEE CONFIDENTIAL INFORMATION
AND INVENTION ASSIGNMENT AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">This Employee Confidential Information and Invention
Assignment Agreement (this &ldquo;<U>Agreement</U>&rdquo;) between me and INmune Bio Inc., a Nevada Corporation (the &ldquo;<U>Company</U>&rdquo;
and, collectively with any and all of its current or future subsidiaries, affiliates, successors or assigns, the &ldquo;<U>Company Group</U>&rdquo;),
is effective as of the first day of my employment by the Company, is a condition of my becoming employed (or my employment being continued)
by the Company, and confirms and memorializes the agreement that (regardless of the execution date hereof) the Company Group and I have
had since my employment&rsquo;s commencement (which, for purposes of this Agreement, includes any service relationship to the Company
or any other member of the Company Group that I may have had prior to becoming an employee) (the date of such commencement, the &ldquo;<U>Effective
Date</U>&rdquo;). I acknowledge that this Agreement is a material part of the consideration for my employment or continued employment
by the Company or any other member of the Company Group (the &ldquo;<U>Relationship</U>&rdquo;). In exchange for the foregoing and other
good and valuable consideration, including my access to and use of Company IP and Confidential Information (in each case as defined below),
I hereby agree to the following:</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">1. <B><U>Confidentiality</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">(a) <B><U>Confidential
Information Definition</U></B>. &ldquo;<U>Confidential Information</U>&rdquo; means any and all information and physical manifestations
thereof not generally known or available outside the Company Group and information and physical manifestations thereof entrusted to the
Company Group in confidence by third parties, whether or not such information is patentable, copyrightable or otherwise legally protectable,
and without regard to whether such information and physical manifestations thereof are marked or otherwise designated as &ldquo;confidential&rdquo;,
&ldquo;proprietary&rdquo;, or something similar. Confidential Information includes, without limitation: (i) Company IP (as defined below);
(ii) IP owned or licensed by the Company Group prior to or outside of this Agreement; (iii) Company Data (as defined below); (iv) access
credentials, such as username, password, security key, security token, or PIN; (v) lists of, or information relating to, employees and
consultants of the Company Group (including, but not limited to, the names, contact information, jobs, compensation, and expertise of
such employees and consultants); and (vi) lists of, agreements with, or information relating to, suppliers and customers (including, but
not limited to, customers of the Company Group on whom I called or with whom I became acquainted during the Relationship) and any other
third parties, price lists, pricing methodologies, cost data, market share data, marketing plans, licenses, contract information, business
plans, financial forecasts, historical financial data, budgets or other business information disclosed to me by the Company Group either
directly or indirectly, whether in writing, electronically, orally, or by observation. Notwithstanding the foregoing, Confidential Information
does not include information that is generally available to and known by the public through no wrongful act of mine or of others who were
under confidentiality obligations as to the item or items involved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">(b) <B><U>Protection
of Information</U></B>. I understand that during the Relationship, the Company intends to provide me with certain information, including
Confidential Information, without which I would not be able to perform my duties to or for the Company. At all times during the Relationship
and thereafter, I shall hold any and all Confidential Information that I obtain, access, or create during the Relationship in strictest
confidence, shall not use such Confidential Information except for the Company&rsquo;s benefit and to the extent necessary to perform
my obligations to the Company in connection with the Relationship, and shall not disclose such Confidential Information to any third party
without written authorization from the Company in each instance. I shall comply with the foregoing obligations whether or not during working
hours, until the information at issue is no longer Confidential Information as described herein. I will not make copies of any Confidential
Information (including any documents, records, files, media, or other resources containing any Confidential Information) except as authorized
by the Company or in the ordinary course of my obligations to the Company in connection with the Relationship. I shall not use Confidential
Information in violation of any applicable laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">(c) <B><U>Third
Party Information</U></B>. During the Relationship and thereafter, I will not improperly use or disclose to the Company Group any confidential,
proprietary or secret information of my former employer(s) or any other person, and I will not bring any such information onto the Company
Group&rsquo;s property or place of business or upload or transfer any such information to the Company Group&rsquo;s property, devices,
or cloud services accounts.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">(d) <B><U>Other
Rights</U></B>. This Agreement is intended to supplement, and not to supersede, any rights the Company Group may have in law or equity
with respect to the protection of trade secrets or confidential or proprietary information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: left; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">(e) <B><U>Permitted Disclosures</U></B>.
Nothing in this Agreement shall be construed to prevent disclosure of Confidential Information as may be required by applicable law or
regulation, or pursuant to the valid order of a court of competent jurisdiction or an authorized Government Agency (as defined below),
provided that the disclosure does not exceed the extent of disclosure required by such law, regulation, or order. To the extent legally
permissible, I shall promptly provide reasonable advance written notice of any such order to an authorized officer of the Company. Without
limiting the generality of the foregoing, nothing herein prohibits or restricts me from engaging in activities protected under applicable
law including communicating with, filing a charge or complaint with, providing documents or information without notice to the Company
Group voluntarily or in response to a lawfully-served subpoena or other information request to, or otherwise participating in any investigation
or proceeding that may be conducted by, the Equal Employment Opportunity Commission, the National Labor Relations Board, the Occupational
Safety and Health Administration, the Securities and Exchange Commission, or any other federal, state, or local government agency or commission
(each a &ldquo;<U>Government Agency</U>&rdquo;), engaging in concerted activities for the purpose of collective bargaining or other mutual
aid or protection, or otherwise disclosing information as permitted by applicable law, regulation, or order protected under Section&nbsp;7
of the National Labor Relations Act or similar state laws, or discussing or disclosing information about harassment, discrimination or
any other conduct that I have reason to believe is unlawful, an unfair employment practice or in violation of a clear mandate of public
policy. Further, this Agreement does not affect my immunity under the U.S. Defend Trade Secrets Act of 2016 (&ldquo;<U>DTSA</U>&rdquo;),
which provides in relevant part as follows:</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25in; text-align: left">(1) An individual shall not be held criminally
or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that (A) is made (i) in confidence
to a federal, state, or local government official, either directly or indirectly, or to an attorney; and (ii) solely for the purpose of
reporting or investigating a suspected violation of law; or (B) is made in a complaint or other document filed in a lawsuit or other proceeding,
if such filing is made under seal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25in; text-align: left">(2) An individual who files a lawsuit for
retaliation by an employer for reporting a suspected violation of law may disclose the trade secret to the attorney of the individual
and use the trade secret information in the court proceeding, if the individual (A) files any document containing the trade secret under
seal; and (B) does not disclose the trade secret, except pursuant to court order.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">2. <B><U>IP
Matters</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">(a) <B><U>Certain Definitions</U></B>.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(i)
&ldquo;<U>IP</U>&rdquo; means any and all: (A) processes, machines, manufactures, compositions of matter, and other potentially
patentable subject matter of any kind, as well as discoveries, ideas, inventions (whether or not reduced to practice), algorithms,
calculations, methods, techniques, technology, equipment, tools, devices, apparatuses, systems, compounds, formulations, designs,
and configurations; (B) written, photographic, audio, video, audiovisual, or other content of any kind (in whatever form embodied),
including without limitation software (in whatever form embodied, including source and executable code), content, textual or
artistic works, videos, graphics, sound recordings, mask works, manuals, documentation, communications, specifications, memoranda,
communications, records, laboratory notebooks, flowcharts, presentations, notes, reports, lists, and other works of authorship and
other potentially copyrightable subject matter of any kind; (C) trade names, trade dress, slogans, logos, trademarks, service marks,
and other source identifiers and other trademarkable subject matter of any kind; (D) social media handles and domains; (E) trade
secrets (including those trade secrets defined under any applicable laws, including without limitation the Uniform Trade Secrets Act
and DTSA), business, technical and know-how data and information, non-public information, and confidential information, including
all know how, processes, customer, client, and personnel lists or data, business and marketing plans, and marketing information and
rights to limit the use or disclosure thereof by any person; (F) data, databases, and data collections of any kind; and (G) any
tangible embodiments, enhancements, improvements, derivatives, or modifications of any kind of any of the foregoing; in each case
with respect to subsections (A) through (G) whether or not any of the foregoing is patentable, copyrightable, trademarkable, or
otherwise legally protectable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(ii) &ldquo;<U>IP
Rights</U>&rdquo; means any and all patent rights, copyright rights, trademark rights, mask work rights, trade secret rights, <I>sui generis</I>
database rights and all other intellectual and industrial property rights of any kind throughout the world (including any rights to apply
therefor, any applications therefor, and the right to claim priority to any such applications, as well as all rights to pursue remedies
for past or future infringement or violation thereof) in or to IP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(iii) &ldquo;<U>Company
IP</U>&rdquo; means, other than Excluded IP: (A) IP that I solely or jointly author, discover, develop, conceive, or reduce to practice
during the period of, or otherwise in connection with, the Relationship or that includes, incorporates, or otherwise relies upon the use
of or results from access to, Confidential Information; (B) any other work product, deliverables, materials, compilations, analyses or
information or any output of AI Technology, in each case that I solely or jointly author, discover, develop, conceive, or reduce to practice
in connection with, or otherwise during the period of, or otherwise in connection with, the Relationship, including without limitation
Confidential Information; and (C) all IP Rights in any of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(iv) &ldquo;<U>Employee
Background IP</U>&rdquo; means IP that, as of the Effective Date: (A) has been created by me or on my behalf; (B) (x) is owned exclusively
by me or jointly by me with others or (y) in which I otherwise have an ownership interest; (C) relates in any way to any of the Company
Group&rsquo;s actual or proposed businesses, products, services, or research and development; and (D) which is not intended to be assigned
to the Company hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(v) &ldquo;<U>Excluded IP</U>&rdquo;
means IP that I solely or jointly author, discover, develop, conceive, or reduce to practice in connection with, or otherwise during the
period of the Relationship that: (A) qualifies fully for exclusion under the provisions of applicable state law, if any, including but
not limited to those attached hereto as Exhibit A; or (B) the IP: (1) was otherwise authored, discovered, developed, conceived, or reduced
to practice entirely on my own time and without the use of any member of the Company Group&rsquo;s equipment, supplies, facilities, or
Confidential Information, (2) did not relate at the time of authorship, discovery, development, conception, or reduction to practice to
any member of the Company Group&rsquo;s business, or actual or demonstrably anticipated research or development, and (3) did not result
from any work performed by me for any member of the Company Group.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">(b) <B><U>Use
or Incorporation of Employee Background IP and Excluded IP</U></B>. If I use or incorporate into any of the Company Group&rsquo;s products,
services, processes, or machines, or create in any Company IP any dependency on, any Employee Background IP or Excluded IP, I will promptly
inform the Company in writing. Whether or not I give such notice, I hereby grant to the Company a perpetual, irrevocable, fully paid-up,
royalty-free, worldwide, fully transferable and sublicensable (through multiple tiers), nonexclusive right and license to practice and
exploit such Employee Background IP and Excluded IP and to make, have made, copy, modify, prepare derivative works of, use, sell, import,
and otherwise distribute and commercialize the product, service, process, machine, or Company IP in which it was used or incorporated,
or with respect to which the Company Group has such a dependency.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(c) <B><U>Company
IP and Excluded IP</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(i) <B><U>Records
and Disclosure</U></B>. I shall keep and maintain adequate and current written records of all IP made or conceived by me (solely, or jointly
with others) during the Relationship, which such records shall be considered Company IP. The records may be in the form of notes, sketches,
drawings, flow charts, electronic data or recordings, laboratory notebooks, or any other format. I will make the records available to
the Company Group on request. I will not remove such records from the Company Group&rsquo;s place of business or systems except as expressly
permitted by the Company&rsquo;s policy which may, from time to time, be revised at the Company&rsquo;s sole election. Without limiting
the generality of the foregoing, I will promptly make full written disclosure to the Company of all IP that I solely or jointly author,
discover, develop, conceive, or reduce to practice during the period of, or otherwise in connection with, the Relationship for, among
other things, the Company to determine which IP is Company IP and which is Excluded IP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(ii) <B><U>Ownership
of Company IP</U></B>. The Company Group and I intend for all Company IP to be owned solely and exclusively by the Company. I acknowledge
that, to the extent permitted by law, all Company IP consisting of copyrightable subject matter is &ldquo;work made for hire&rdquo; as
defined in the Copyright Act of 1976 (17 U.S.C. &sect;101), are fully compensated by my salary, and such copyrights are therefore owned
by the Company. With respect to all other Company IP, or to the extent not otherwise vested in the Company by operation of law, I will
hold in trust for the sole right and benefit of the Company, and hereby assign to the Company, or its designee, for no additional consideration,
all of my right, title and interest in and to any and all Company IP. I further hereby waive and irrevocably quitclaim to the Company
or its designee any and all claims, of any nature whatsoever, that I now have or may hereafter have for infringement of any Company IP.
If I have any rights to Company IP that cannot be assigned to the Company, I hereby grant to the Company a perpetual, irrevocable, fully
paid-up, royalty-free, worldwide, fully transferable and sublicensable (through multiple tiers), exclusive right and license to practice
and exploit such rights and to make, have made, copy, modify, prepare derivative works of, use, sell, import, and otherwise distribute
and commercialize any Company products or services that may practice such rights. Without limiting the generality of the foregoing, to
the extent I have any rights of attribution, paternity, integrity, modification, disclosure and withdrawal, and any other rights throughout
the world that may be known as or referred to as &ldquo;moral rights,&rdquo; &ldquo;artist&rsquo;s rights,&rdquo; &ldquo;droit moral,&rdquo;
or the like (&ldquo;<U>Moral Rights&rdquo;)</U> in Company IP that cannot be assigned or exclusively licensed under applicable law, I
hereby waive and agree not to enforce any such Moral Rights, including without limitation any limitation on subsequent modification, to
the extent permitted under applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(iii) <B><U>Further Assurances;
Power of Attorney</U></B>. During and after the Relationship, I agree to reasonably cooperate with the Company, at the Company&rsquo;s
expense and within the Company&rsquo;s timeframe, to: (i) apply for, obtain, perfect, and transfer to the Company all Company IP; and
(ii) maintain, protect, and enforce the same, including without limitation by participating in litigation and regulatory proceedings,
as well as executing and delivering to the Company any and all applications, oaths, declarations, affidavits, waivers, assignments, and
other documents and instruments requested by the Company. I hereby irrevocably grant the Company a power of attorney to execute and deliver
any such documents on my behalf in my name and to do all other lawfully permitted acts to transfer the Company IP to the Company and further
the transfer, issuance, prosecution, and maintenance of all IP Rights therein, to the fullest extent permitted by law, if I do not promptly
cooperate with the Company&rsquo;s requests (and without limiting any other rights or remedies the Company may have in such circumstances).
The foregoing power of attorney is coupled with an interest and shall not be affected by my subsequent incapacity.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Publicity</U></B>.
I hereby consent to any and all uses and displays by the Company Group and its agents of my name, voice, likeness, image, appearance,
and biographical information in any media, at any time during or after the Relationship, for all legitimate promotional, marketing, and
educational purposes of the Company Group in connection with the Relationship. I hereby forever release the Company Group and its directors,
officers, employees, and agents from and against any and all claims, actions, damages, losses, costs, expenses, and liabilities of any
kind, arising under any legal or equitable theory whatsoever, relating to any such permitted use of any of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">3. <B><U>Privacy</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(a) <B><U>Personal
Information Definition</U></B>. &ldquo;<U>Personal Information</U>&rdquo; means information that identifies, relates to, describes, is
reasonably capable of being associated with, or could reasonably be linked, directly or indirectly, with a particular individual or household.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">(b) <B><U>Privacy
Notice</U></B>. I acknowledge that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(i) the
Company Group collects certain Personal Information about me, which may include contact information, identification materials, demographic
information, professional information, education and training information, financial information, benefits information, security credentials,
information about my activity on and use of the Company Group&rsquo;s facilities and its telecommunications, networking and information
processing systems, as well as other work related information. The Company Group may collect such information directly from me as well
as from supervisors, colleagues, customers, vendors, publicly available sources and other third parties I may interact with as an employee
of the Company. In addition, the Company Group may also collect this information through service providers and other third parties that
collect it on the Company Group&rsquo;s behalf, such as communications providers, payroll providers and benefits providers; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(ii) the
Company Group uses my Personal Information in the ordinary course of business for purposes such as: recruiting, onboarding, staffing,
leave, personnel evaluations, promotions, performance management, training, discipline; supporting and managing personnel; managing access
to or use of company systems, facilities, records, property and infrastructure; monitoring employee conduct and compliance with the Company
Group&rsquo;s policies and practices; improving efficiency; compensation, payroll, and benefit planning and administration; managing business
travel; communicating with and between personnel, as well as with designated emergency contacts; investigating, documenting and reporting
work-related injuries, illnesses, or grievances; conducting other internal investigations, audits, and risk assessments; fulfilling contractual
obligations to personnel and third parties; and complying with applicable laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">4. <B><U>Company
Property</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">(a) <B><U>Company Equipment;
Returning Company Documents</U></B>. I acknowledge that I have no expectation of privacy with respect to the Company Group&rsquo;s telecommunications,
networking or information processing systems (including, without limitation, files, email messages, and voice messages) and that my activity
and any files or messages on or using any of those systems may be monitored or reviewed at any time without notice. I further acknowledge
that any property situated on the Company Group&rsquo;s premises or systems and owned by the Company Group, including storage media, filing
cabinets or other work areas, is subject to inspection by the Company Group&rsquo;s personnel at any time with or without notice. At the
time of termination of the Relationship, I will deliver to the Company (and will not keep in my possession, recreate or deliver to anyone
else) any and all devices, records, data, notes, reports, proposals, lists, correspondence, specifications, drawings, blueprints, sketches,
laboratory notebooks, materials, flow charts, equipment, other documents or property, or reproductions of any of the aforementioned items
developed by me pursuant to the Relationship or otherwise belonging to the Company Group.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">(b) <B><U>Company
Data</U></B>. I acknowledge that my work may involve dealing with information (including Confidential Information) relating to the Company
Group&rsquo;s customers, potential customers, end-users, suppliers, potential suppliers, employees, independent contractors and other
personnel, and others with whom the Company Group has a relationship, including, without limitation, unique identifiers, financial, health,
educational, biometric, online activity, location, employment details, and derived profiles (collectively, &ldquo;<U>Company Data</U>&rdquo;).
I am aware of the need to adhere to privacy laws such as the Health Insurance Portability and Accountability Act (HIPAA) for health information,
and the Fair Credit Reporting Act (FCRA), among other laws and regulations related to Company Data. I will protect Company Data with strong
security measures, restricting data access to authorized personnel, and ensuring compliance with legal standards for handling and disclosing
such information. If a data breach occurs, I will promptly report it and assist in the response. I will also follow the Company&rsquo;s
privacy policies, stay informed about privacy obligations, and participate in necessary training. I will treat Company Data as confidential
and in compliance with all applicable laws, and will not collect, use, retain or disclose Company Data for any purpose other than as necessary
for the purpose of performing legitimate business activities within the scope of the Relationship. I acknowledge that failure to adhere
to the policies, procedures, contractual restrictions, and instructions that the Company Group has implemented to protect the privacy
and security of Company Data is a violation of the terms of my employment. I further acknowledge that, without limiting other potential
remedies, any such failure may result in termination of my employment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">5. <B><U>Non-Solicit</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">(a) <B><U>Generally</U></B>.
As described above, I acknowledge that the Company Group&rsquo;s Confidential Information includes information relating to the
Company Group&rsquo;s customers, potential customers, end-users, suppliers, potential suppliers, employees, independent contractors,
and other personnel, and others, and I will not use or disclose such Confidential Information except as authorized by the Company in
advance in writing. I further agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(i) <B><U>Employees
and Independent Contractors</U></B>. During the Relationship, and for a period of twelve (12) months immediately following the termination
of the Relationship for any reason (the &ldquo;<U>Restriction Period</U>&rdquo;), whether with or without cause, I shall not, directly
or indirectly, solicit any of the Company Group&rsquo;s employees or independent contractors with whom I have worked or otherwise had
contact during the Relationship or with respect to whom I have Confidential Information to terminate their relationship with the Company
Group, either for myself or for any other person or entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(ii) <B><U>Other
Parties</U></B>. During the Relationship, I will not solicit or influence or attempt to influence any actual or potential customer, either
directly or indirectly, to direct any purchase of products and/or services to any person, firm, corporation, institution or other entity
in competition with the business of the Company Group.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">(b) <B><U>Notice
to Third Parties</U></B>. During the Restriction Period, I shall inform any entity or person with whom I may seek to enter into a business
relationship (whether as an owner, employee, independent contractor or otherwise) of my contractual obligations under this Agreement.
I acknowledge that the Company Group may, with or without prior notice to me and whether during or after the Relationship, notify third
parties of my agreements and obligations under this Agreement. To the fullest extent permissible under applicable law, upon written request
by the Company Group, I will respond to the Company Group in writing regarding the status of my employment or proposed employment with
any party during the Restriction Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">6. <B><U>Representations
and Covenants</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">(a) <B><U>AI Technology</U></B>.
Without limiting any of my other obligations under this Agreement, I will not: (i) input any Confidential Information (including, without
limitation, any Company Data) into any software, application, technology or platform that leverages machine learning (including, without
limitation, any artificial intelligence, generative artificial intelligence, predictive artificial intelligence, and other applied statistics)
(collectively, &ldquo;<U>AI Technology</U>&rdquo;); or (ii) use any AI Technology or any output of any AI Technology in connection with
the Relationship, including, without limitation, in the development of any Company IP; in each case of (i) or (ii), except in accordance
with the Company&rsquo;s then-current policies and procedures (if any) or as otherwise expressly authorized by the Company in writing.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">(b) <B><U>Facilitation
of Agreement</U></B>. I shall execute promptly, both during and after the end of the Relationship, any proper oath, and to verify any
proper document, required to carry out the terms of this Agreement, upon the Company&rsquo;s written request to do so.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">(c) <B><U>No
Conflicts</U></B>. I acknowledge and agree that I have a duty of loyalty to the Company during the course of the Relationship. Without
limiting the generality of the foregoing, to the fullest extent permitted under applicable laws, while I render services to the Company,
I will not engage in, launch, or encourage others to launch any other company, venture, employment, consulting project or other business
activity (whether on a full- or part-time basis) that would create a conflict of interest with the Company Group or that would, directly
or indirectly, constitute my engagement in or participation in any business that is competitive in any manner with the Company Group&rsquo;s
business, nor will I solicit or influence or attempt to influence any actual or potential customer to direct any purchase of products
and/or services to any person, firm, corporation, institution or other entity in competition with the business of the Company Group with
respect to such products and/or services. I represent and warrant that my performance of my duties for the Company and all the terms of
this Agreement does not and will not breach any agreement I have entered into, or will enter into, with any third party (including without
limitation any former employer), including without limitation any agreement to keep in confidence proprietary information or materials
acquired by me in confidence or in trust prior to or during the Relationship. I will not induce the Company Group to use any inventions,
confidential or non-public proprietary information, or material belonging to any previous client, employer or any other party. I shall
not enter into any written or oral agreement that conflicts with the provisions of this Agreement without the Company&rsquo;s prior written
consent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">(d) <B><U>Voluntary
Execution</U></B>. I certify and acknowledge that I have carefully read all of the provisions of this Agreement, that I understand and
have voluntarily accepted such provisions, and that I will fully and faithfully comply with such provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">7. <B><U>Acknowledgment</U></B>.
I acknowledge that the duties to be performed by me for the Company are of a special and unique character, that I will obtain
knowledge and skill relevant to the Company&rsquo;s industry, methods of doing business, and marketing strategies by virtue of my
employment, and I agree that the terms of this Agreement are reasonable under such circumstances. I further acknowledge that the
amount of my compensation reflects, in part, my obligations and the Company&rsquo;s rights under this Agreement and I have no
expectation of any additional compensation, royalties, or other payment of any kind in connection with my performance of this
Agreement, that I will not be subject to undue hardship by reason of my full compliance with this Agreement or the Company&rsquo;s
enforcement thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">8. <B><U>Miscellaneous</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">(a) <B><U>Governing
Law</U></B>. The validity, interpretation, construction and performance of this Agreement, and all acts and transactions pursuant hereto
and the rights and obligations of the parties hereto shall be governed, construed and interpreted in accordance with the laws of the state
in which I am employed by the Company, or, if I am a remote employee, reside, without giving effect to any principles of conflict of laws
that would lead to the application of the laws of another jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">(b) <B><U>Entire
Agreement</U></B>. This Agreement sets forth the entire agreement and understanding between the Company and me relating to its subject
matter and merges and supersedes all prior discussions between us, provided that this Agreement shall not supersede or be superseded by,
and shall be read in conjunction with, any arbitration agreement, non-solicitation, and confidentiality agreement or other restrictive
covenants entered into between the parties to the fullest extent permitted under applicable law. No amendment to this Agreement will be
effective unless in writing signed by both parties to this Agreement. The Company shall not be deemed hereby to have waived any rights
or remedies it may have in law or equity, nor to have given any authorizations or waived any of its rights under this Agreement, unless,
and only to the extent, it does so by a specific writing signed by a duly authorized officer of the Company, it being understood that,
even if I am an officer of the Company, I will not have authority to give any such authorizations or waivers for the Company under this
Agreement without specific approval by the Board of Directors. Any subsequent change or changes in my duties, obligations, rights or compensation
will not affect the validity or scope of this Agreement.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">(c) <B><U>Successors
and Assigns</U></B>. This Agreement will be binding upon my heirs, executors, administrators and other legal representatives, and my successors
and assigns, and will be for the benefit of the Company, its successors, and its assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">(d) <B><U>Notices</U></B>.
Any notice, demand or request required or permitted to be given under this Agreement shall be in writing and shall be deemed
sufficient when delivered personally or by overnight courier or sent by email, or forty-eight (48) hours after being deposited in
the U.S. mail as certified or registered mail with postage prepaid, addressed to the party to be notified at such party&rsquo;s
address as set forth on the signature page, as subsequently modified by written notice, or if no address is specified on the
signature page, at the most recent address set forth in the Company&rsquo;s books and records.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">(e) <B><U>Severability</U></B>.
If one or more of the provisions in this Agreement are deemed void or unenforceable to any extent in any context, such provisions
shall nevertheless be enforced to the fullest extent allowed by law in that and other contexts, and the validity and force of the
remainder of this Agreement shall not be affected. The Company and I have attempted to limit my right to use, maintain and disclose
the Company Group&rsquo;s Confidential Information, and to limit my restrictions only to the extent necessary to protect the Company
Group from unfair competition. Should a court of competent jurisdiction determine that the scope of the covenants contained in this
Agreement exceeds the maximum restrictiveness such court deems reasonable and enforceable, the parties intend that the court should
reform, modify and enforce the provision to such narrower scope as it determines to be reasonable and enforceable under the
circumstances existing at that time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">(f) <B><U>Remedies</U></B>.
I acknowledge that violation of this Agreement by me may cause the Company irreparable harm, and therefore I agree that the Company
will be entitled to seek extraordinary relief in court, including, but not limited to, temporary restraining orders, preliminary
injunctions and permanent injunctions, in addition to and without prejudice to any other rights or remedies that the Company may
have for a breach of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">(g) <B><U>Advice
of Counsel</U></B>. I acknowledge that, in executing this agreement, I have had the opportunity to seek the advice of independent legal
counsel, and I have read and understood all of the terms and provisions of this Agreement. This Agreement shall not be construed against
any party by reason of the drafting or preparation hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">(h) <B><U>Survival</U></B>.
The terms and provisions that reasonably should survive the termination or expiration of this Agreement in order to give proper
effect to its nature or intent shall survive such termination or expiration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: left; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">(i) <B><U>Counterparts</U></B>.
This Agreement may be executed in any number of counterparts, each of which when so executed and delivered shall be deemed an original,
and all of which together shall constitute one and the same agreement. Execution via an electronic signature system, facsimile copy or
scanned image will have the same force and effect as execution of an original, and an electronic signature, facsimile or scanned image
signature will be deemed an original and valid signature.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[<I>Signature Page Follows</I>]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">The parties have executed this Employee Confidential Information and
Invention Assignment Agreement on the respective dates set forth below, to be effective as of the Effective Date first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2"><FONT STYLE="text-transform: uppercase"><B>The Company:</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 60%">&nbsp;</TD>
  <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 35%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2"><B>INmune Bio Inc.</B></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">/s/ David Moss</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2" STYLE="text-align: center">(Signature)</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>Name:</TD>
  <TD>David Moss</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>Title:</TD>
  <TD>Chief Executive Officer</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>Address:</TD>
  <TD></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2">225 NE Mizner Blvd., STE 640</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2">Boca Raton, FL 33432 USA</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>Date:</TD>
  <TD>November 26, 2025</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2"><FONT STYLE="text-transform: uppercase"><B>EMPLOYEE</B></FONT><B>:</B></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>By:</TD>
  <TD STYLE="border-bottom: Black 1.5pt solid">/s/ Mark Lowdell</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2" STYLE="text-align: center">(Signature)</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>Name:&nbsp;</TD>
  <TD>Mark Lowdell, PhD</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2">Date: November 26, 2025</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-13-</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>inmb-20251126.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.3a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 86o5s7xRiXhun8uDb31cWauOGaPty5BxKZkxsmx/HWk6Hy4pPZ7vPSqPQ1b2gdAD -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:INMB="http://inmunebio.com/20251126" elementFormDefault="qualified" targetNamespace="http://inmunebio.com/20251126">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://inmunebio.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="inmb-20251126_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="inmb-20251126_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
    <import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
    <import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
    <import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
    <import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>inmb-20251126_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.3a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>inmb-20251126_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.3a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="inmb-20251126.xsd#Cover" roleURI="http://inmunebio.com/role/Cover" />
    <link:presentationLink xlink:type="extended" xlink:role="http://inmunebio.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Nov. 26, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov. 26,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38793<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">INMUNE
    BIO INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001711754<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-5205835<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">225
NE Mizner Blvd.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 640<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boca Raton<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">33432<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">561<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">710-0512<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, par value $0.001 per shares<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">INMB<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="ea0267546-8k_inmune.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inmunebio.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="ea0267546-8k_inmune.htm">ea0267546-8k_inmune.htm</File>
    <File>inmb-20251126.xsd</File>
    <File>inmb-20251126_lab.xml</File>
    <File>inmb-20251126_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea0267546-8k_inmune.htm": {
   "nsprefix": "INMB",
   "nsuri": "http://inmunebio.com/20251126",
   "dts": {
    "inline": {
     "local": [
      "ea0267546-8k_inmune.htm"
     ]
    },
    "schema": {
     "local": [
      "inmb-20251126.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "inmb-20251126_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "inmb-20251126_pre.xml"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 23
   },
   "report": {
    "R1": {
     "role": "http://inmunebio.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2025-11-26",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0267546-8k_inmune.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-11-26",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0267546-8k_inmune.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CountryRegion",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Extension",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12gTitle",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://inmunebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001213900-25-115921-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-25-115921-xbrl.zip
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M[FK2G_:%)7(C,T\8<"&(!*#]E#JZH3JYL75TM=Y/K*/[UJN.T!Y"ZZ\N'@?
MH IT9>W.+N)4O>%P*"5,I)P60Z4=Y4[UHD3U:P!/L/2+.L_,+QA]2#<9B#3
MV%,PAV?<B9D0H7CFC&%:+I2,"XT$!; O.M=\P6!6'=9-%#)9C9RP'NAU5Z@2
M6R=<@/:TA40E7&;"H6"7>A>=A#PD%=/7K>&FAZ34Z]G<<O"X"I_,]L-=GUD2
M2XR/2$D(U,38&J9I)::;9Y9^\5:"QKQX:4N9\"HE*-*4VH*I9<=2[4L,^FM8
M4XN$[\I*S-2N3)%J#=\20XZYC1>$,F0#S0Z\1:1E#WVK5WW*'6Z"I6.0$PJF
M"_F0(4BFE#)20LWPZA&Y%DRJ]T:H#N4.9ZW0_4,526%& B3/]IS,,:5I0.D,
MN0Y91LHDBVF5(DTPYRQ+W36PR!BY7(#;I?# A(W<-*$Q*'F G1)\U1&1U*1B
MA'[H?PK9; K< !4'I9;E=A7@'.U#WN9X^ =0@-I@"#^ C&W MC.XU 5#Q0(#
MP;9ON3@36H3$ 2(R +6+QA\JET+V3_S548ZUZAT"(I4 BU!0M$31OD1\+75I
M"[L8="1]].&Y >XPH.M?WO!O"A&=F@QM2X)531?L\?Y.(@(,D_ 8!IP#\!-M
M<"^ "6'=80*[I_808 4PV\$L!_+M^8SCOY7'-]JGY4%7$7@ $*-@D3QU&]A,
MO1)'S6"0.E,7MHW$M%0"/^?\,!I\QAH5P(G7)D"U@9#Z0[2$W24.H*BD!GY[
M\NE+,S8/1#E#;GL $O4O8JGM#Q9#V*8:T(_N@(RJ ;#G9DHY.J[5!QC1=;%%
M^&:/OSB^H '&C/!NEQEXM<@<$;\3XLB&3.A<(M^FB'2;7V [1G@#80TM&_I-
M+H AF>C#'DO<7J .=-.6* >&7WI8+?LT*FM!^(%HH;H?YA5RAA6%8:M6WS9!
MFZ&NNV%"O7H%2;X1C0;.4]:;,>I8O4+(]*Z3!>IU@V^2W!Y199K5'794F6%=
MZ2EQF E=:V'@BP(]K1LG>N#ON] +^HR (<P4# _C4S+6MX$R1N6=4OP)+: )
M=!C;A5?']1)H:-;E;E>2#=#0J."'2O.J-\"A]G6"+IM*AWNL.D8$XQ)^]H)"
M9<+VB![S-D<42 N#$59:L+[MI4VIU2<2K5WU.3%>4=58,)/AB-!*-RGORC73
M_XCM6<$<'V!N8(NU"?I6)FA(<#V+$=VM$"7BK4S/KCP=1]I\/RRP+\FC]F5B
M8?9E",Y'S$R4S_]HNX6HF9E8N)FY_9B9N58-/V081BC]-/LP_R/V(5I=LW9:
M(L9.(V]MIX668EQP8FRND;6Y]@N8:W.5V]IH6QMM2P1?%+)'#B&T0W*EE)\\
MP.']X[9#\@DSX=[NC.+'LEZ?]O;#R$N'/?P/";YA[("4!&UR/7@/,:Y1S4;,
M<Y%SBJ"7.C5;GZ#\ E+"BQ?VP&"FN79K?DID':37VX!AW[K@70[;&.Q<9-"!
M#0Z\@P%NQ[#!2 Z6F!A-68J1H'QCW"H(YJ6>%%/W]EM,PB,^*Z1P>J*[0L!C
M+.$#=AO@#0:"9Y^A?]70N5\1=^Q@16&#R5LMU*5@!@2+D/ ]I/6V]F+X;E5Y
MI/F>*5IG/AG'@5*IRC(A$9&&C]$/E+%G>DV821DF(;IFPE,DP(ZBW)(3WF)C
M.WYJB"X=H8.+B5>!(R#'IQH!/WM.#EI(& +W<)L<KV*RCG3![!KW9T.= 7O#
M=B-!@I2GC%%N=)RX.K^5&5)2*^$?V 9F69-98.LZ4R= S=$4Y"G_L@,"#S9M
M!]UJ&$PZ,O!@QO$)F0@5S5HS^)LPN"+>.# R'5=!3/.'^>DS//0Y1HI7E#4/
M^@W=#]!U5/A.@\\3B7#XI8ETM_#X4OBG<8\'8F!^SVO0O,A+Q.D)>0R^2"C'
M1Q=<510A>-K3-+GL &_[/'EL4V%$9&\Z0(1I#QR+NH(K[3MPT2U!^5 H!B@$
M4N_ @BITO?=IC,77%PWTJMJ"@H]$^Y2;N& )I48L#L@#V"!Q%EL[YS^0',MQ
MX1-(MY'2,([OCD=8W\4XC],!_B<;^4W? _7)209>,2S,4P1]F,(LE\#7!18P
M.7.1][RGL]HM0VXBGQ-S@4 3P7:=8"1D_[; $YLNL#YH:A=3KX,WLWC9@=)7
MYA6KC9Q,3#K(8(7'J:UA/)T,\_8X>!2"P?;ST6'U5;(E=25@;##J=#S$53P"
M6QH8G>(F=T:I&8$)!2DDZS.A! ^\&A#CL(L_+;*)D,CB4:RK4G\,9GAE!*42
M)%P)E10*XP/18O!1VQ-HG$F,0 4$9OU^19D)@*K$HFZZ$A0=AE$F(*BT4\L1
M5'<0!Y] P 03>CBA*(^/O[<U+J]H++OHXB6=6%M:4<F L717@EN+' [D::FL
M%TX]EN06AN.0:[SM!HMGFIB)A@1$$X*A0J!2@H?O<?ZX7B;V )L%F9G*4#U,
ML("^NGR< 0*;D2LL+X3JF2>3816? NA\$FL;-U+UK9B<W69"4L-!JKO6^%48
M@1W4<@$%Z214BK2CA!%5D[*I0/35O),0MBW:U.+? L?'\-^H*^?8CF'S<WF9
M8A68%B,R;5MEG;M=F(E/3A_B^%D]O&12"ADD=H5#OTB;@$VH8 35Z/@=IC F
M5Z=N'-@1S*(1,&D+K"=DNQ#3J' 63J,L^\G,@>F-X[8X,A_%NSX=WD2S/9?-
M@"\)/S4%!/R13P';XTM4T>,T0<S4',"\9<^/]>L()X!EQP5L/>D+WCH$4X"Z
M9 !Z$ZU]']:E9[CPS^6%-<C1W<]D<Z'#6?4^"8_3D!@!?9<\9W;9%WO#V$R$
MEG)9P?PY-57F7F$9W]" +TW:DP!G\-?;OE,XYC3AV9CN+[HDA,]/P:NOOE?$
MPZ?6)+R/V$SH\.>$^M\OIK&0]5CXJ]A/&'C]O.>]?_+M*V"(=G-#RVZGM/Q>
M2BL4-E]>"F.1ZX+[<AQ;/$;M9\!)"3C"K:,DHUEM9[>PO9/-L6$NF\[=<PN#
MZIF.TUWL_=79,Y&4RE8P2$QDO\F< 0-W?#I+=Y(?CS;4>'WHVW'+9^^.WI*P
MB/836$1;?A:9SF_[&8RRM&HE_XH\L[AM81[WY2/<MPB>B3DX5$P4/LCS..=M
M]Z6ETC3;J\ T9:"X4("H) 9%6NH=G)Y0AWKO7]Y IC#P,@>&;/SX?M7"=YR0
MN^/ZQ3B&$BIL\2I55%;LHO=TMD]^G=CC)?9HZ\2>'W0 7NO:[!N\>:Q1/:N5
M;F[KE<9*@O\V*V^REK-(P(.K!0D_^NG%[%DT\/UX7:-47+$2PS5'WG&8X44\
MA8IT^J?6>(K@G4=AW+3).M1L83 6!U(!>;\!ACY=3!-2PU'7Z=@"@#=^A3I)
MJU2H=[FKK3]21P_L/_SV**F]8"E?NTA\$PL8WM8J"MKCZA78TN69&-;R5,U?
M?I*]+H3+0XG'WS.WL]BH(IC[[,"/L 9>X)[G!;Y:L?\Q+HLM(GP\.G@,Y->J
M:#V-U*)+(_/BEMQ2R(3C>?SW5B/+INU7"%3%10JZ2&1XS44_GS0K!*I*Z5;0
M3<KI^%G=;UE2-_#U%AK4^6E3Y%_7'_Z))0FGM]F?6'3P"=2-Q+:<() U-(:'
MI'JB_KC/[AW?J\0S[^70")KJQCX,3[\8E?/V0^ECO;E5:@V_:)]O[5JK51J>
M__,@Z^7ZSMW=^?D'0ZMK>O[KPY:X^,1OZ;%-_V5[>T;U;E3/YFAN]/Z8?1K<
MW6K7GQVGU/YTUSNMW^V7"M+)_GU\HXM^V?SR^;.]*V[V!M4]UOZG<'':$&*W
M<#RZ'33HZ>7I\&QT<WY>_>?+S67U9%2]&-:_93NM3_]<TW.G6\Z5M-N;DZQP
M/ERT]&S5N=MI]%CV[]:-[)P]W/T[Y%KY\_6P=/K/Q_K[,[=Q\_?93OO\Y*+S
M]Z=:H=HU=O8O=W+LDW5;'72;IU_Z^6_R6[:_F^V/]./SSQ^/CKP5V6K:Q@A_
M=YRN6?Q_4$L#!!0    ( !=H?%N(**GQ?30  *#]   <    96$P,C8W-30V
M,#%E>#$P+3%?:6YM=6YE+FAT;>U]Z6_;R++O=P'Z'_H%[PYL0%9L9SE)G!O
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M:)BLL-];NL2!Z?U%,"%6;][UBW2],\;X0)I*02.%IDC,!K&/Z^>)+\MEBB]
MK^RN<R16FAU@',D4<LJ0P87;<[FZX'-Q^\'-M Z# XP"[?>6&A$[U#*'9EGQ
M'6]NFJ=!RP,,,G"">T*V,+CP38TP/<(45FI-#R?#@3"(+59+0J077=9KJ&[T
MU%I!W7GD!30XD:F7#,\QCI53V&'_8E_6 \9[N7(Y?&WI=6'0F_DXM.O?M"(7
MX@EK<S\_[EU0T;<H_CY8W+2Q&-U%,IR6%@[/J#*$ T1L[7.7GW(FCD3X2^ER
MW\D:X#$RM:YX7KP.KC::%%46$8RQSC!4;,-4P15V%GLN5[4@,@#VG+>U+M/)
M1-M[ XS4%?G !68<:#5B7YG^AH1>Z?<D2MA>(Z;KEB^3'/"2<,QX;/B]B+W=
M"!PVK!@UP ]W*_" "[@IVL"]0&2Y1B]=N\YE_6G!+X+U(#R?49*"@H^+29[^
MB7Y4:T5 9=M-)BC*\KP/FZ>2NR/#$4=TTV_F7:-&T74L,O"\GM:W1PMS/4$X
M'?\21M0HB&%QPR_K#XLN#*51RMA _FV5&1 3]&_%-]?@@]?Q[364<(DZO/E'
MD/$8,O:Y!AO6%1/./1(%X"-1BK7Y54/5B%1O*: -29]* ;EQW7Q8;\IU E@@
MM;;U9-V%@ENH;SX5N;M>"%PQF[.,PJ",*9[V(.M9^E%S\0D[=5@DB9L@]TE*
MX(-R?E+A%Z*7*&#@[H+PJ _DP+>BROO>TD_<,P%L&V5(.KG?,]OC;HE:XL=?
M15_@R)N^4"9ST^IN9QFN7?[G,F2N:QP^:)HB$3-<%_)(J]7A#A_CA]5]\YI.
M*Y@>-CUJSS;840W6W*?4+L&VC[HNQ/:-)*D*7ET0TV.=Y%JTW629ZXRM(%&#
MYJ_I-I44S:@.W8LOV%VP@Q?K)ISQF;5T*OE@31ZBB[ ,1/5K/)0;1)SNW+F]
MA=S*HR'X_*.T=LG772#R05IAE/)>]C0 DFQYW>J07PR%M-PZB$83MJ2S\)&,
MFV48EXOJ_5Q['[SBB.FI+!PP*MG9Y3L*E^A,T+XPU^E2=3H#]X9, P]VV>;O
MUQRY#G9W%ROUGU.A]/Y0_8(MTW:V-K:>!F N;,CHO$M"50H< !M:!_TN!RN4
M/7 02!-XBSH/L#;&;IK8U3WE((7<"NA@OY$W3]M\!.O)#.T&TDZ&T*K21 #3
ML:( @)YD <G-BMP(A5"C+RPB(P?;N$[%5.$KL05E3#=C:6/%>"T;<!ND*P%>
MO 6_=N"6, VT$U8K77>;EU=1BADO*H1##)JT/4+RP50:;!\!%C.M>GW'H3:(
MZSY?E_6U0PJ=0>S#:=C['<["F[/#PZ/C-^KB1%V\/3I7NV=[1Q=GNQ=')\?J
M].QD__#@P]GA0.V=7+Q5OY]\4+O'!_#@H=H_>7^Z>_R[^FWWZ-^'])NSHS=O
M+_ [9X?G)^_@E_CG\P_[;]7!T?GIAXO#<WCL[.3#F[=J5UV<'>V^4SB#7S^<
M_:Y.SM2O'P[>'.)_V(>.U>[!^Z/CHW.:#WR0YG-X -.]I\)KVQYY3!/O2@GT
MPEV8&MD_^RJ5L@K8)X2!Z, L=/F;*:&F,VP5NNE""_:X'$\YG?9L>D<3P>I^
M=U;OH'N(Q\"2\X<2W!]=& UR@BQO<F+8L@0O\PKOR+:XH;:\<.*"RF,C-PPY
M>HQ02DL64/2VQ/7NB3G@\\XC,*"-*]_O[4?S*,:M/\DSX1\T#HP8=H1>)I"[
M6SNP7+/4:QIP/3$XR2-JE&J4!\. <R_(@'=1T\18;P4P/?,NA?KF,%/0+N,Q
M1=YHWJ AR<.#'ZK*W$AH8ML8OBE1)/)?28U(-0#%C:C"--::X<,Y_/V/@LQ;
M;AMNF\\[\6M8<.P!,J5,@?1)3>4'K5.)]H'$-,TGPX_U>V'6L/W%@6UL0LVO
ML7 6FZ!<"B[4%!>%BW-4<8LD6Z=V,$_;Y':)]5Q9#*X]RB4&I!H^T-P72+<[
M9LLER"[^SR\TN>C:B +;5&.!JU^KJ'6AGC#1S6YCEM05442R#NN9X6HX%QV#
MGB11@6.75.C#9$3;Q@FFNW#T;RW+^?1GEE.RG$]_9CG_UNKIL>_-]'NG>+(K
MN0I^-P].L"?$EED9#K7+PC%AZ4A7]J ?D04"V5QAWL3B!OT*EC3U%P_F@X^]
MI\8E7%U+@2<@QE$>#_W^DK_NOC\/T",@FO:*.,(T+*K)UQE87$G$/<Q\0#&Y
M>QQ*7BSU&7FI<HD<8=F<M,515=E@>Q83MP^=5,]]L/[J6G09I1D732&86R*?
MXIU5U%8$&[J@+VJ?!!WQ\L.K:5W/7SQ\>'5U-?PCFE514@[C8O:09N!UF-_P
M-NTAW7ME2@I;;B5YP]94M1%A2J^)'N/-H5)'E/1YI3-SC<1RUJ#[ALB[PY9)
MKA 72S8E^B\I@K;1S$ZEG4Y@)E.^#D9.$.!7<^D@LM=B!>$IZLT4WV$/,JVJ
M!I&6MF^=SV:)C@F,3-%VTWZB#N9H%P+'0_SK,3O>E6%F,O!-([.(\6W.L86/
M745ELN/*F:A'&J_R3^)!X/<K;E!(V9Z(,$K8M\>$.99<X,X)_U:;WTKKCUWM
M'.1&O&LR\=_$R@%-QIKM#^P^[*X?<'%6_C(]Y2$/B'<D/\-.M(EFRG:H*TTE
M,K'I*M*:XQTP$VY9!#_!P#!R7*+VR1PEZ8MGI"-=T?9$^;,PE;OB&1A37$D[
MR%Q,=\]'G&$=/,4B@K!0Q9W!:KY3@P)001F27" @=K*!!EP3P!(!PL&JVN3,
MEHYM;@AO?4!Z)LTQ"#1W#6WZO17QMQ LG.:70&/LA%UD&6>%LT7[6I(E!'?=
MB(\X@,X-G(B!J426%E:2?2XWTFGKM[E($%6#C$VXWQ]$92GGR_!FB,'2)P0,
M.J:,(#D\<C@(KIMY'7%D9 MDI+M//[?;]_!L/87=_*/)8W8USW26ZC$QWFL*
M39R@?2W6SG&!"=5)Q^4*:J0QM<N,(=CP)1*9XZ6C6O)!J9T 1E!A?+F+"F6>
M][T4E+YI3X#M6Q5>'N9=2RO*Q9;+T,'Q]I:L-0ZXL!(1#WR% 6?3U<#-S'7D
M"9B*UC^:9,)9+,DFR=&C,TNX;5J =<-)/Y,_^T=3IA68<O:(B]?)L (I>+UW
MG/@8Y/D;0;B<VHIOTU>^U9@W0 @P9ZWH,S((VFZ1U.(;-%V%JI</87.Z#2*0
MR[!L$8:1(J(5J*! $'T(R]$8F)3,0QC7U+-1D:2^P2--,\5T\KO;?W[@88LN
M=(6=L"B5%QBT&QXJSI_F)K")S3#:H2:Z+= 8?Z@QJ :A<.$*+L<'$Q5>J3)N
M0!%1*(IK#:6NN$:H!A9E)M)O@S_!9:X\-/ 0G, 2[Y+2?,=9.)%JJ-Y[F$2*
MBE&O7(&LM:MAEDR3,3^5-UU!-+9[:1BSE>_&Y6;55L3!9M;8EL5$"0E*0R99
MM[NS--]8[B6%31Z'ZC=PE*BVQ $IT260=G*5-=*7=E6PJ2.V#XFRTK& $:,C
M'10F)HHU_K+KXP:4FN%B\.M'3Q'"DQE0D5@1H-DS]GVH"MP+H!GQ:B!,KD2\
M&XU#_TR>[_=\^2C5T3(811EE/,%[>4-2OSK7!2;B2S2]$*A;FU^J'@X'Q$!/
M=BG92TUM8)*!U]8BD-]F+P()']:LVWX7\.Q'K>>H::P4X][H%C$APH$5UU64
M7K()2GZI;5H>="A8=G^[85T8$'E6FMKX'.+.K3&A:7SJ3#/RB_7)\Z2))#*N
MJ71A^))1G7Y+=2D;"4A^#9>Q4/-3X2WK G.Y4L-%R7"FKH$;%V-)LBB?$U<%
M+N07:6F8E&P@6DA5%2565%&/*_@/?*HR^5OX$WNP"5;N5NS^5J'SB#;#&-:
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M+?(?E&N?\#8*DV+!EB;<F=V$TJCE=NL2+/@VWX$U\?:6>AM3__?K0C?&OL;
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M,"TR7VEN;75N92YH=&WM?>M/&\FV[W=+_A_JCNX9@62<0!XS"3F1@# )<Y.
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MHFOI_V BD4CH]T#Z_@7" ^>"4CA!D;+0R[(@L9TT8[8YD,51P,^*+ 'AS[^
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M/?YX&,SJ35RVMQ5D WEU/C!FM5J_-PI<;!@'EC-N:C-4[U#1:W4 2F-*5#H
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M0L9BAUD!Z<$ 5X$R2*C6^CUQK<FG&"9#0PPWG4Z+?QEX9CQN%L*_I<\ED[<
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M344=-((>&\AJU40C[&?90J-<D;9<V>6'VMQTLP1AO+^>A?'[%095&.(YE16
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M26O)K",_8,L2+CJ1TO,5)2>;3A$RXL#KWFF3<@T<,;;[*AR:>9--*0U5E':
M\+?=LI8ZAB+#:/W>%1FIN\<N#_J]P/=R;*.NXAI?F$%A.&_A!5\*C#NIT?4.
M(VV3"=HI=DPD3H/;\^XCHMIFN$L,0K\W'9_*^I.V8URW@H!UGPX$96DSYRB.
MVB ?&Y>N@V(WQI]C98WR[Q:46D$+MX9M]!V40L#01I-3OB$LJ]3 D/Q7_RVI
MB@I#[N(&9&VCWH4(KTK@;^ZR<^H54&?-_9XHSP -!WL&+G+%:3PI.,!"3-T
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M=2 0 ]M?^E\L-_%".,DP:X*TISEW4:?/D,_B5?/$)!C%&TAO )PPP@^B'LS
MA%R)3$5S\I-5E %!-C@2/%\T9(S6G#6=@2^&VC[JN8XR 2$C,.;F0/:G<I@?
MR?4/V";@=/D6'@4"$CCJL7-?*NQ[4,S3L>MIG+?]*A]* ;<-%[&&"03'MG;/
MR1+1,6)'N[=#6[]]@\P"U\23L<<^L#5"WL?/!'L=?BC<]$G\V4"8L$=@9\C'
MAZP7:[QPM &\[KI[!.F=-^",Q_T%^#0%^Q0'5]H;(% /(A?98;8)*XA+_#1.
MWTU16N'[0TJFGL;ZS-9W>6W@+,W)/K1 (1M5L3^#)8.<I=M"\01^?XJ_OVJE
MMR$]=&,IZ$<_4M"2@G[T(P7]S1J'*QII4 %DT$G#B='@5-O:Q;7'OF,=M"(Y
MH6;H&@.H!N.;PB)',C _T(7S]E-+O^!GU+JOB,&V<G42"I,5]GLKESBPK;\(
M),3J+;AVD6Y8Q@ ?2%,I9Z2X5#?P<?4\\66Y1/$IZ)6]30[#2JL##"+9,DX9
M4MQOVZ"1KRWX6-!^<#VMP]  JT#[O95&Q"XUS*%95GRYFY_F2=3P ",,G-Z>
MDBT,_GM3(TB/$(65VC##Z7 @#.)*U9(8YT67]%JJ6SVU45!O'GD!#4YDZA7#
M<X!C[11VV;\XD/6 \5ZN70Y?5WI5#/1Z/@[M^M]:4;^W<OAKC'L;5/0-BK]W
M#C5M+49_B0PGI87#,ZH+X>@06_O<XZ><BR,1_U(ZW'=2!GB,;*4KGI>@@:L+
M)>G*X8$QT!G'B5V,*KJ[SB'/Y9H6A 7 GO.VUF4ZG1IW9X"5NB(?Y')ZKC\0
ML:]L>T/"KO1[$B)LKQ%S=:N720YX22AF/#;\GF9O5X/#AO6B%O;A;P,></DV
M11NX$X@LU^JE*]>YJCTM^$6P'@3G,T92,/#C8IJG_T$_JK4BH++K)1.59 7>
MATM2R:61\8@CNN$W"^Y/H] ZEA@$7D_KVZ.EO9H@GDYX^R)J%$2P^.'#[K!6
M J(+0SF4<FP!_Z[&#(@)^K?B6VOPP:OX]@I*^"P=WOHCN'B,%X=<@TVTBBDG
M'HD"\!&=8F5^U5 M(E5;"F)#<J=2/FY=MQ#4FW*5 )9';6P_VO1QX!;FFT]%
M[J\6 E?,)2QU')2QI=,!8#U+WQLN/6&G#DLD<1/D(DD)?%#"3^K[8NP2!0S\
M/1 !]8$<^):N@N^M_,0=$\"N38;DDGU32']#U H__E)_@B-ONT+9M$VKMYUC
MN';QGT^/^:9Q^*!MB43,<%7((ZW6ASM"A!_6]BUJ.JU@>KC<J#O;8$<U6'&?
M4K,$USSJJA#;WR1)5?#JHI@>ZR2?Q[K.,C<96$&B!LU?VVLJ*9I1';L7G["[
M8 <O-VTXXR-KZ=3QP9H"/!<!&8CJ5W@HUX@XW;IS^W<3*P^&X/"/TMIGH_>
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M^#F=TAQM;X8K9,D=V^9'! +TUCC)SK@6WR' ?#D\H?RPP:.[7"7#V_+$;45
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M5/N0O&,N_ZPQ7+@4:?[A&5*MU%1&S'=57^8H5ZKH\05&M\#GH*K$#$<C*UK
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M.>EO%V2&#] GL:V0COS!+J)/3?G!%KR"IR=OZ-GTZ#RK.9.$OXTW.DH3&P2
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M&N0-F7+]B5YW;V-GQ->G&?Q)/]C^0_:$9;L^HXR)Z-*,PL=\GAW"':)[9'#
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M8!+Y J709Q:]SS'S/=832"3O<?+8T-19O2L[=,&%AYKE93C:B@W&2GH@@;X
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MKG$0=I8?'IOQ4>M-'S/HU'\'FXKKR$(SNJX2BVQ!FPHZP\S\D<W:66R;<1J
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M=YZ(V\5>\+ :MD+24H:'BLU>'S!E#!)!/DZL*USE#0WKJV1:N;M7@"VV#J\
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M4$L! A0#%     @ %VA\6SH?9(,J P  Y0L  !$              ( !K\0
M &EN;6(M,C R-3$Q,C8N>'-D4$L! A0#%     @ %VA\6YAD-N[]"@  ?X8
M !4              ( !",@  &EN;6(M,C R-3$Q,C9?;&%B+GAM;%!+ 0(4
M Q0    ( !=H?%L[SMOA60<  -97   5              "  3C3  !I;FUB
G+3(P,C4Q,3(V7W!R92YX;6Q02P4&      < !P#H 0  Q-H

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>ea0267546-8k_inmune_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="inmb-20251126.xsd" xlink:type="simple"/>
    <context id="AsOf2025-11-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711754</identifier>
        </entity>
        <period>
            <startDate>2025-11-26</startDate>
            <endDate>2025-11-26</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2025-11-26" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2025-11-26" id="Fact000004">0001711754</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2025-11-26" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2025-11-26" id="Fact000010">2025-11-26</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2025-11-26" id="Fact000011">INMUNE     BIO INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2025-11-26" id="Fact000012">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2025-11-26" id="Fact000013">001-38793</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2025-11-26" id="Fact000014">47-5205835</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2025-11-26" id="Fact000015">225 NE Mizner Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2025-11-26" id="Fact000016">Suite 640</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="AsOf2025-11-26" id="Fact000017">Boca Raton</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2025-11-26" id="Fact000018">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2025-11-26" id="Fact000019">33432</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2025-11-26" id="Fact000020">561</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2025-11-26" id="Fact000021">710-0512</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2025-11-26" id="Fact000022">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2025-11-26" id="Fact000023">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2025-11-26" id="Fact000024">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2025-11-26" id="Fact000025">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2025-11-26" id="Fact000026">Common     Stock, par value $0.001 per shares</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2025-11-26" id="Fact000027">INMB</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2025-11-26" id="Fact000028">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2025-11-26" id="Fact000029">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
